{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Sanjaisharma.jpg|frameless|upright=0.3|center]]
|<big>[[User:Sanjaisharma|Sanjai Sharma, MD]]<br>Visalia, CA</big>
|-
|}
''Are you looking for a regimen but can't find it here? It is possible that we've moved it to the [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==ASBMT==
*'''2016:''' Kharfan-Dabaja et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116249/ Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation]

==[http://www.esmo.org/ ESMO]==
*'''2016:''' Ladetto et al. [http://annonc.oxfordjournals.org/content/27/12/2149.full.pdf+html ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia] [https://www.ncbi.nlm.nih.gov/pubmed/27701070 PubMed]
*'''2015:''' Eichhorst et al. [http://annonc.oxfordjournals.org/content/26/suppl_5/v78.full.pdf+html Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/26314781 PubMed]
*'''2013:''' Ghielmini et al. [http://annonc.oxfordjournals.org/content/24/3/561.full.pdf+html ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)] [https://www.ncbi.nlm.nih.gov/pubmed/23175624 PubMed]

==International Workshop on Chronic Lymphocytic Leukemia (iwCLL)==
*'''2018:''' Hallek  et al. [http://www.bloodjournal.org/content/131/25/2745.long iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL] [https://www.ncbi.nlm.nih.gov/pubmed/29540348 PubMed]
===Older===
*'''2008:''' Hallek et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972576/ Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines]
*'''1996:''' Cheson et al. [http://www.bloodjournal.org/content/87/12/4990.long National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment] [https://www.ncbi.nlm.nih.gov/pubmed/8652811 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf NCCN Guidelines - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma]

=First-line therapy, randomized data=

==Alemtuzumab monotherapy {{#subobject:9ca7b3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:54cc87|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/25/35/5616.long Hillmen et al. 2007 (CAM 307)]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Chlorambucil_monotherapy|Chlorambucil]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''This regimen was intended for patients who were at least 18 years old with flow cytometry–confirmed diagnosis of B-cell CLL, Rai stage I through IV with evidence of progression according to the [[#NCI_Sponsored_International_Working_Group_Criteria_.281999.29|National Cancer Institute Working Group (NCI-WG) 1996 criteria]], no previous chemotherapy for CLL, a life expectancy of at least 12 weeks, [[Performance_status#ECOG_performance_status_.28WHO.2FZubrod_score.29|WHO performance status]] of 0 to 2, and adequate renal and liver function.''
====Chemotherapy====
*[[Alemtuzumab (Campath)]] as follows:
**3 mg IV once per day, then increased as tolerated in terms of infusion reactions to 10 mg IV once per day, and then to 30 mg IV once per day
**Once 30 mg dose is tolerated: 30 mg IV over 2 hours, 3 times per week

====Supportive medications====
*''See references for details, as they differ by paper.''
*[[Diphenhydramine (Benadryl)]] 50 mg PO once 30 minutes prior to [[Alemtuzumab (Campath)]]
*[[Acetaminophen (Tylenol)]] 650 mg PO once 30 minutes prior to [[Alemtuzumab (Campath)]] 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO 3 times per week, starting on day 8, continuing at a minimum until 2 months after treatment is complete
*[[Famciclovir (Famvir)]] 250 mg PO twice per day, starting on day 8, continuing at a minimum until 2 months after treatment is complete

'''Up to 12 to 16 weeks of therapy''' 

''Total course varies depending on reference.''

===References===
# Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007 Dec 10;25(35):5616-23. Epub 2007 Nov 5. [http://jco.ascopubs.org/content/25/35/5616.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17984186 PubMed]

==Bendamustine monotherapy {{#subobject:694d2f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a166c6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/27/26/4378.long Knauf et al. 2009]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Chlorambucil_monotherapy|Chlorambucil]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''This regimen was intended for previously untreated CLL patients up to 75 years of age with [[#Binet_staging_.281981.29|Binet stage]] B or C disease in need for treatment per the [[#NCI_Sponsored_Working_Group_Criteria_.281996.29|NCI-WG guidelines]] or [[#International_Workshop_on_Chronic_Lymphocytic_Leukemia_guidelines_.282008.29|IWCLL guidelines]].''

====Chemotherapy====
*[[Bendamustine]] 100 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''28-day cycle for 6 cycles'''

===References===
<!-- Presented in part at the Annual Meeting of the American Society of Hematology, Atlanta, GA, December 6-9, 2008, and San Francisco, CA, December 8-11, 2007. -->
# Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 10;27(26):4378-84. Epub 2009 Aug 3. [http://jco.ascopubs.org/content/27/26/4378.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19652068 PubMed]
## '''Update:''' Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Merkle K, Montillo M. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol. 2012 Oct;159(1):67-77. Epub 2012 Aug 4. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12000/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22861163 PubMed]
# '''Retrospective:''' Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. Ther Adv Hematol. 2013 Jun;4(3):157-71. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666446/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23730494 PubMed]

==BR {{#subobject:7542a2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine & '''<u>R</u>'''ituximab
<br>R-B: '''<u>R</u>'''ituximab & '''<u>B</u>'''endamustine
===Regimen {{#subobject:da5692|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/26/3209.long Fischer et al. 2012 (GCLLSG CLL2M)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30051-1/abstract Eichhorst et al. 2016 (GCLLSG CLL10)]
|style="background-color:#1a9851"|Phase III (E)
|[[#FCR|FCR]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/ Michallet et al. 2018 (MABLE)]
| style="background-color:#1a9851"|Phase IIIb (E)
|[[#Chlorambucil_.26_Rituximab|R-Clb]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 0 
**Subsequent cycles: 500 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 6 cycles based on response and toxicity'''

===References===
# '''GCLLSG CLL2M:''' Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012 Sep 10;30(26):3209-16. Epub 2012 Aug 6. [http://jco.ascopubs.org/content/30/26/3209.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22869884 PubMed]
# '''Retrospective:''' Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. Ther Adv Hematol. 2013 Jun;4(3):157-71. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666446/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23730494 PubMed]
<!-- # '''Abstract:''' Barbara Eichhorst, MD, Anna-Maria Fink, MD, Raymonde Busch, PhD, Elisabeth Lange, MD, Hubert Köppler, Prof. Dr., Michael Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, MD, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Marek Trneny, MD, Ph.D., Prof, Kirsten Fischer, MD, Hartmut Döhner, MD, Michael Kneba, MD, Clemens Wendtner, MD, Wolfram Klapper, Karl-Anton Kreuzer, Dr. med., Stephan Stilgenbauer, MD, Sebastian Böttcher, MD, and Michael Hallek, MD. Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG). 2013 ASH Annual Symposium abstract 526 [http://www.bloodjournal.org/content/122/21/526 link to abstract] -->
# '''GCLLSG CLL10:''' Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. Epub 2016 May 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30051-1/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27216274 PubMed]
# '''MABLE:''' Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1. [http://www.haematologica.org/content/103/4/698 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29419437 PubMed]

==CC {{#subobject:719404|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CC: '''<u>C</u>'''ladribine, '''<u>C</u>'''yclophosphamide

===Variant #1, 0.36/650 {{#subobject:add51b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.bloodjournal.org/content/108/2/473.long Robak et al. 2006 (PALG CLL2)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cladribine_monotherapy|Cladribine]]
|style="background-color:#d9ef8b"|Might have superior CR rate
|-
|2. [[#CMC|CMC]]
|style="background-color:#fc8d59"|Seems to have inferior CR rate
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 0.12 mg/kg IV over 2 hours once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1

====Supportive medications==== 
*No routine prophylactic antibiotics, antiviral agents, or growth factor administration was planned.

'''28-day cycle for up to 6 cycles'''

===Variant #2, 0.36/750 {{#subobject:99a67c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/28/11/1863.long Robak et al. 2010 (PALG-CLL3)]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#FC|FC]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 0.12 mg/kg IV over 30 minutes once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 to 3

====Supportive medications====
*"No routine prophylaxis with antibiotics, antiviral agents, or growth factors."

'''28-day cycle for up to 6 cycles'''
===References===
# '''PALG CLL2:''' Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; Polish Leukemia Group (PALG CLL2). Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21. [http://www.bloodjournal.org/content/108/2/473.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16551966 PubMed]
## '''Update:''' Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Mar;55(3):606-10. Epub 2013 Nov 14. [https://www.tandfonline.com/doi/full/10.3109/10428194.2013.809073 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23721512 PubMed]
<!-- Presented at the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL; the 12th Congress of the European Hematology Association, June 7-10, 2007, Vienna, Austria; the XII International Workshop on Chronic Lymphocytic Leukemia, September 14-16, 2007, London, United Kingdom; the 49th Annual Meeting of the American Society of Hematology, December 8-11, 2007, Atlanta, GA; the 13th Congress of the European Hematology Association, June 12-15, 2008, Copenhagen, Denmark; and the 50th Annual Meeting of the American Society of Hematology, December 6-9, 2008, San Francisco, CA. -->
# '''PALG-CLL3:''' Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszyñska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010 Apr 10;28(11):1863-9. Epub 2010 Mar 8. [http://jco.ascopubs.org/content/28/11/1863.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20212251 PubMed]

==Chlorambucil & Obinutuzumab {{#subobject:50878e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GClb: '''<u>G</u>'''A101 (Obinutuzumab) & '''<u>C</u>'''h'''<u>l</u>'''oram'''<u>b</u>'''ucil

===Regimen {{#subobject:9c3473|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = "2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa1313984 Goede et al. 2014 (GCLLSG CLL11)]
|rowspan = "2" style="background-color:#1a9851"|Phase III (E)
|1. [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Chlorambucil_monotherapy|Chlorambucil]]
|style="background-color:#1a9850"|Superior OS
|-
|2. [[#Chlorambucil_.26_Rituximab|Chlorambucil & Rituximab]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Obinutuzumab (Gazyva)]] as follows:
**Cycle 1: 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once per day on days 8 & 15 
**Cycles 2 to 6: 1000 mg IV once on day 1
*[[Chlorambucil (Leukeran)]] 0.5 mg/kg PO once per day on days 1 & 15

'''28-day cycle for 6 cycles'''

===References===
<!-- # '''Abstract:''' Valentin Goede, Kirsten Fischer, Kathryn Humphrey, Elina Asikanius, Raymonde Busch, Anja Engelke, Clemens M. Wendtner, Olga Samoylova, Tatiana Chagorova, Marie-Sarah Dilhuydy, Javier De La Serna Torroba, Thomas Illmer, Stephen Opat, Carolyn Owen, Karl A Kreuzer, Anton W Langerak, Matthias Ritgen, Stephan Stilgenbauer, Michael Wenger, Michael Hallek; German CLL Study Group. Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. J Clin Oncol 31, 2013 (suppl; abstr 7004) [http://meetinglibrary.asco.org/content/116249-132 link to abstract] -->
# '''GCLLSG CLL11:''' Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10. Epub 2014 Jan 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1313984 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24401022 PubMed]
## '''Update:''' Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 Jul;29(7):1602-4. Epub 2015 Jan 30. [https://www.nature.com/leu/journal/v29/n7/full/leu201514a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25634683 PubMed]

==Chlorambucil & Ofatumumab {{#subobject:c168f0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:c88f0b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60027-7/fulltext Hillmen et al. 2015 (COMPLEMENT 1)]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Chlorambucil_monotherapy|Chlorambucil]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 10 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once on day 8
**Cycle 2 onwards: 1000 mg IV once on day 1

====Supportive medications==== 
*Premedication for [[Ofatumumab (Arzerra)]] included [[Acetaminophen (Tylenol)]], [[:Category:Antihistamines|antihistamines]], and [[:Category:Steroids|glucocorticoids]] (no doses or further information provided)

'''28-day cycle for a minimum of 3 cycles, and then given until best response up to a maximum of 12 cycles'''

===References===
<!-- # '''Abstract:''' Hillmen P, Tadeusz R, Janssens A, Govindbabu K, Grosicki S, Mayer J, Panagiotidis P, Kimby E, Schuh A, Boyd T, Montillo M, McKeown A, Carey J, Gupta I, Chang C, Lisby S, Offner F. Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). ASH 2013 Annual Meeting abstract 528. [https://ash.confex.com/ash/2013/webprogram/Paper58498.html link to abstract] -->
# '''COMPLEMENT 1:''' Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, Doubek M, Panagiotidis P, Kimby E, Schuh A, Pettitt AR, Boyd T, Montillo M, Gupta IV, Wright O, Dixon I, Carey JL, Chang CN, Lisby S, McKeown A, Offner F; COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015 May 9;385(9980):1873-83. Epub 2015 Apr 13. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60027-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25882396 PubMed]

==Chlorambucil & Rituximab {{#subobject:af2f90|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RClb: '''<u>R</u>'''ituximab & '''<u>C</u>'''h'''<u>l</u>'''oram'''<u>b</u>'''ucil
<br>CLB-R: '''<u>C</u>'''h'''<u>L</u>'''oram'''<u>B</u>'''ucil & '''<u>R</u>'''ituximab 

===Variant #1, Clb 0.5 mg/kg q2wk {{#subobject:bdacc9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = "2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa1313984 Goede et al. 2014 (GCLLSG CLL11)]
|rowspan = "2" style="background-color:#1a9851"|Phase III (E)
|1. [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Chlorambucil_monotherapy|Chlorambucil]]
|style="background-color:#1a9850"|Superior PFS
|-
|2. [[#Chlorambucil_.26_Obinutuzumab|Chlorambucil & Obinutuzumab]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 0.5 mg/kg PO once per day on days 1 & 15
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 6 cycles'''

===Variant #2, Clb 8 mg/m<sup>2</sup>/d, 1 week out of 4 {{#subobject:ab165a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/ajh.23668/full Foà et al. 2014]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 8 mg/m2/day PO once per day on days 1 to 7
*[[Rituximab (Rituxan)]] as follows:
**Cycle 3: 375 mg/m<sup>2</sup> IV once on day 1
**Subsequent cycles: 500 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 8 cycles'''
====Subsequent treatment====
*Responders (PR or better): [[#Observation_2|Observation]] versus [[#Rituximab_monotherapy_2|Rituximab maintenance]]

===Variant #3, Clb 10 mg/m<sup>2</sup>/d, 1 week out of 4 {{#subobject:8723f7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876343/ Hillmen et al. 2014 (NCRI CLL208)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/ Michallet et al. 2018 (MABLE)]
| style="background-color:#1a9851"|Phase IIIb (E)
|[[#BR|BR]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 10 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1

'''28-day cycles for 6 cycles'''
====Subsequent treatment====
*NCRI CLL208: Patients not achieving CR could have up to 6 more cycles of chlorambucil alone
*MABLE: Patients not achieving CR could have up to 6 more cycles of chlorambucil alone or until CR

===References===
<!-- # '''Abstract:''' Valentin Goede, Kirsten Fischer, Kathryn Humphrey, Elina Asikanius, Raymonde Busch, Anja Engelke, Clemens M. Wendtner, Olga Samoylova, Tatiana Chagorova, Marie-Sarah Dilhuydy, Javier De La Serna Torroba, Thomas Illmer, Stephen Opat, Carolyn Owen, Karl A Kreuzer, Anton W Langerak, Matthias Ritgen, Stephan Stilgenbauer, Michael Wenger, Michael Hallek; German CLL Study Group. Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. J Clin Oncol 31, 2013 (suppl; abstr 7004) [http://meetinglibrary.asco.org/content/116249-132 link to abstract] -->
# '''GCLLSG CLL11:''' Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10. Epub 2014 Jan 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1313984 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24401022 PubMed]
## '''Update:''' Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 Jul;29(7):1602-4. Epub 2015 Jan 30. [https://www.nature.com/leu/journal/v29/n7/full/leu201514a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25634683 PubMed]
<!-- # '''Abstract:''' R Foa, A Alietti, A Guarini, S Ciolli, F Di Raimondo, G Del Poeta, F Lauria, F Forconi, A Cuneo, A Cortellezzi, F Nobile, V Callea, M Brugiatelli, M Massaia, S Molica, L Trentin, R Rizzi, G Specchia, L Orsucci, A Ambrosetti, M Montillo, L Zinzani, F Ferrara, F Morabito, M Mura, S Soriani, S Santangelo, M Marinelli, M De Propris, A Alietti, J Runggaldier. A PHASE II STUDY OF CHLORAMBUCIL+RITUXIMAB (CLB-R) FOLLOWED BY R MAINTENANCE VS OBSERVATION IN ELDERLY PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INDUCTION PHASE RESULTS. EHA Annual Meeting 2011, Abstract 0532 [http://www.ehaweb.org/congress-and-events/20th-congress/previous-congresses-2/abstract-book link to abstract book] -->
# Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014 May;89(5):480-6. Epub 2014 Feb 18. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23668/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24415640 PubMed]
# '''NCRI CLL08:''' Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE, Kennedy DB, Pettitt AR, Nathwani A, Varghese A, Cohen D, Rawstron A, Oertel S, Pocock CF. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol. 2014 Apr 20;32(12):1236-41. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1236.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876343/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24638012 PubMed]
# '''MABLE:''' Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1. [http://www.haematologica.org/content/103/4/698 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29419437 PubMed]

==Cladribine monotherapy {{#subobject:3ae1a1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 0.36 {{#subobject:8cab02|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.bloodjournal.org/content/108/2/473.long Robak et al. 2006 (PALG CLL2)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#CC|CC]]
|style="background-color:#fee08b"|Might have inferior CR rate
|-
|2. [[#CMC|CMC]]
|style="background-color:#d73027"|Inferior CR rate
|-
|[https://www.tandfonline.com/doi/abs/10.3109/10428194.2014.893306 Mulligan et al. 2014]
|style="background-color:#1a9851"|Phase III (E)
|1. [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Chlorambucil_monotherapy|Chlorambucil]] 2. [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Fludarabine_monotherapy|Fludarabine]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm. Dosing details for Mulligan et al. 2014 were not available in the abstract.''
====Chemotherapy====
*[[Cladribine (Leustatin)]] 0.12 mg/kg IV over 2 hours once per day on days 1 to 5

====Supportive medications==== 
*No routine prophylactic antibiotics, antiviral agents, or growth factor administration was planned.

'''28-day cycle for up to 6 cycles'''

===Variant #2, 0.7 {{#subobject:57becf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/13/3/570.long Saven et al. 1995]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 0.1 mg/m2/day IV continuous infusion on days 1 to 7 (total dose per cycle: 0.7 mg/m<sup>2</sup>)

'''28 to 35-day cycles, repeated until maximum response or limiting toxicity'''

===References===
# Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 1995 Mar;13(3):570-4. [http://jco.ascopubs.org/content/13/3/570.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7884417 PubMed]
# '''PALG CLL2:''' Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; Polish Leukemia Group (PALG CLL2). Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21. [http://www.bloodjournal.org/content/108/2/473.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16551966 PubMed]
## '''Update:''' Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Mar;55(3):606-10. Epub 2013 Nov 14. [https://www.tandfonline.com/doi/full/10.3109/10428194.2013.809073 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23721512 PubMed]
# Mulligan SP, Karlsson K, Strömberg M, Jønsson V, Gill D, Hammerström J, Hertzberg M, McLennan R, Uggla B, Norman J, Wallvik J, Sundström G, Johansson H, Brandberg Y, Liliemark J, Juliusson G; Scandinavian and Australasian Leukaemia Lymphoma Groups (Allg). Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Dec;55(12):2769-77. Epub 2014 Apr 16. [https://www.tandfonline.com/doi/abs/10.3109/10428194.2014.893306 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24524339 PubMed]

==CMC {{#subobject:25f5b2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CMC: '''<u>C</u>'''ladribine, '''<u>M</u>'''itoxantrone, '''<u>C</u>'''yclophosphamide

===Regimen {{#subobject:c2431|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.bloodjournal.org/content/108/2/473.long Robak et al. 2006 (PALG CLL2)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cladribine_monotherapy|Cladribine]]
|style="background-color:#1a9850"|Superior CR rate
|-
|2. [[#CC|CC]]
|style="background-color:#91cf60"|Seems to have superior CR rate
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 0.12 mg/kg IV over 2 hours once per day on days 1 to 3
*[[Mitoxantrone (Novantrone)]] 10 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 6 cycles'''

===References===
<!-- Preliminary results of this study were presented at the 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, December 6-10, 2002; and at the 10th International Workshop on CLL, Stresa, Lake Maggiore, Italy, October 10-12, 2003; and at the 46th Annual Meeting of the American Society of Hematology, San Diego, CA, December 4-7, 2004; and at the 11th International Workshop on CLL, New York, NY, September 16-18, 2005. -->
# '''PALG CLL2:''' Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; Polish Leukemia Group (PALG CLL2). Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21. [http://www.bloodjournal.org/content/108/2/473.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16551966 PubMed]

==FCA {{#subobject:68d031|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FCA: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''lemtuzumab
<br>FCCam: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>Cam</u>'''path (Alemtuzumab)
===Regimen {{#subobject:218cde|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/119/22/5104.long Lepretre et al. 2012 (GOELAMS CLL2007FMP)]
|style="background-color:#1a9851"|Phase III (E)
|[[#FCR|FCR]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://www.bloodjournal.org/content/123/21/3255.long Geisler et al. 2014 (HOVON-68)]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#FC|FC]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
'''''GOELAMS CLL2007FMP''' was halted prematurely due to excess mortality. In '''HOVON-68''', this regimen was intended for patients with previously untreated CLL diagnosed and in need of treatment according to the [[#NCI_Sponsored_Working_Group_Criteria_.281996.29|National Cancer Institute guidelines]], 18 to 75 years of age, with [[Performance_status#ECOG_performance_status_.28WHO.2FZubrod_score.29|WHO performance status]] less than 3 and no severe comorbidities, with high-risk CLL as defined by the presence of either unmutated IGHV, [[#Risk_by_FISH_.282000.29|17p deletion, 11q deletion, or trisomy 12 by FISH]].''
====Chemotherapy====
*[[Fludarabine (Fludara)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> PO once per day on days 1 to 3
*[[Alemtuzumab (Campath)]] as follows:
**Cycle 1: 30 mg SC once per day on days -1, 0, and 1
**Subsequent cycles: 30 mg SC once on day 1

====Supportive medications====
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS) | Cotrimoxazole]] 400/80 mg PO once per day until 6 months after end of treatment
*[[Acyclovir (Zovirax)]] 400 mg PO three times per day until 3 months after end of treatment
OR
*[[Valacyclovir (Valtrex)]] 500 mg PO twice per day until 3 months after end of treatment

'''28-day cycle for 6 cycles'''

===References===
<!-- # '''Abstract:''' Lepretre S, Aurran T, Mahe B, Cazin B, Tournihlac O, Maisonneuve H, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du Sang" (GOELAMS) : CLL2007FMP (for fit medically patients). Blood 2009;114:538. [http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/538?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=CLL2007FMP&searchid=1&FIRSTINDEX=0&volume=114&issue=22&resourcetype=HWCIT link to abstract] -->
# Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10. Epub 2012 Feb 14. [http://www.bloodjournal.org/content/119/22/5104.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22337714 PubMed]
<!-- Presented in abstract form at the 53rd annual meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011, and the XV International Workshop on CLL, Cologne, Germany, September 8-11, 2013. -->
# Geisler CH, van T' Veer MB, Jurlander J, Walewski J, Tjønnfjord G, Itälä Remes M, Kimby E, Kozak T, Polliack A, Wu KL, Wittebol S, Abrahamse-Testroote MC, Doorduijn J, Ghidey Alemayehu W, van Oers MH. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood. 2014 May 22;123(21):3255-62. Epub 2014 Apr 15. [http://www.bloodjournal.org/content/123/21/3255.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24735962 PubMed]

==FCM {{#subobject:f6adfc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FCM: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''itoxantrone

===Variant #1 {{#subobject:e76bd1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08317.x/full Hillmen et al. 2011 (NCRI CLL201)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#R-FCM|FCM-R]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Fludarabine (Fludara)]] 24 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Cyclophosphamide (Cytoxan)]] 150 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Mitoxantrone (Novantrone)]] 6 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 6 cycles'''

===Variant #2 {{#subobject:455511|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://clincancerres.aacrjournals.org/content/14/1/155.long Bosch et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3
*[[Mitoxantrone (Novantrone)]] 6 mg/m<sup>2</sup> IV over 30 minutes once on day 1

====Supportive medications====
*[[:Category:Granulocyte_colony-stimulating_factors|Granulocyte colony-stimulating factor]] 300 mcg SC once per day on days 1 to 7
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day on days 1 to 5

'''28-day cycle for 6 cycles'''

===References===
# Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008 Jan 1;14(1):155-61. [http://clincancerres.aacrjournals.org/content/14/1/155.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18172266 PubMed]
<!--
# Hillmen P, Pocock C, Cohen D, Cocks K, Sayala HA, Rawstron A, et al. NCRI CLL201 trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. Blood 2007;110(11):752.
# Hillmen P, Pocock C, Cohen D, Gregory W, Cocks K, Rawstron AC, et al. NCRI CLL201 Trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. British Journal of Haematology 2008;141(Suppl 1):119.
-->
# Hillmen P, Cohen DR, Cocks K, Pettitt A, Sayala HA, Rawstron AC, Kennedy DB, Fegan C, Milligan DW, Radford J, Mercieca J, Dearden C, Ezekwisili R, Smith AF, Brown J, Booth GA, Varghese AM, Pocock C; NCRI CLL Sub-Group. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. Br J Haematol. 2011 Mar;152(5):570-8. Epub 2011 Jan 14. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08317.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21231927 PubMed]

==FCR {{#subobject:1dc12c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FCR: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''ituximab
<br>R-FC: '''<u>R</u>'''ituximab, '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide
===Variant #1, 25/250/375-500 {{#subobject:17f90c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://jco.ascopubs.org/content/23/18/4079.full Keating et al. 2005]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961381-5/fulltext Hallek et al. 2010 (GCLLSG CLL8)]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#FC|FC]]
|style="background-color:#1a9850"|Superior OS (*)
|style="background-color:#eeee01"|Equivalent HRQoL
|-
|[http://www.bloodjournal.org/content/119/22/5104.long Lepretre et al. 2012 (GOELAMS CLL2007FMP)]
|style="background-color:#1a9851"|Phase III (C)
|[[#FCA|FCCam]]
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[http://www.bloodjournal.org/content/122/21/524 Schweighofer et al. 2013 (GCLLSG CLL7)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#1a9850"|Superior EFS
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30051-1/abstract Eichhorst et al. 2016 (GCLLSG CLL10)]
|style="background-color:#1a9851"|Phase III (C)
|[[#BR|BR]]
|style="background-color:#91cf60"|Seems to have superior PFS
|
|-
|}
''Note: efficacy for '''GCLLSG CLL8''' is based on the updated 2016 results.''
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 0
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*''Note: these vary according to reference.''
*[[Diphenhydramine (Benadryl)]] 25 mg IV once 30 minutes prior to [[Rituximab (Rituxan)]] 
*[[Acetaminophen (Tylenol)]] 650 mg PO once 30 minutes prior to [[Rituximab (Rituxan)]]
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day on days 1 to 7 of cycle 1
*Some patients received:
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO twice per week
**[[Valacyclovir (Valtrex)]] 500 mg PO once per day
*[[:Category:PCP_prophylaxis|PCP (Pneumocystis jirovecii pneumonia) prophylaxis]] recommended for severe leukopenia greater than 7 days
*No routine prophylaxis with antiviral medications or G-CSF

'''28-day cycle for 6 cycles'''

===Variant #2, 25/250/500 {{#subobject:dg134c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13061/full Awan et al. 2014 (LUCID)]
|style="background-color:#1a9851"|Phase III (C)
|FCR+L
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] as follows:
**Cycle 1: 25 mg/m<sup>2</sup> IV over at least 10 to 30 minutes once per day on days 2 to 4
**Cycle 2 to 6: 25 mg/m<sup>2</sup> IV over at least 10 to 30 minutes once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] as follows:
**Cycle 1: 250 mg/m<sup>2</sup> IV over at least 10 to 30 minutes once per day on days 2 to 4
**Cycle 2 to 6: 250 mg/m<sup>2</sup> IV over at least 10 to 30 minutes once per day on days 1 to 3
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 50 mg/m<sup>2</sup> IV over 4 hours once on day 1, then 450 mg/m<sup>2</sup> IV once on day 3
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Cotrimoxazole]] or [[:Category:PCP_prophylaxis|equivalent]]
*[[Acyclovir (Zovirax)]] 400 mg PO twice per day or [[:Category:Antivirals|equivalent]]
*[[:Category:Hematopoietic_growth_factors|Growth factors]] at physician discretion

'''28-day cycle for 6 cycles'''

===Variant #3, 20/150/375-500 ("FCR-Lite") {{#subobject:44cd18|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/27/4/498.long Foon et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 2 to 4
**Cycles 2 to 6: 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] as follows:
**Cycle 1: 150 mg/m<sup>2</sup> IV over 60 minutes once per day on days 2 to 4
**Cycles 2 to 6: 150 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1, then 500 mg/m<sup>2</sup> IV once on day 14
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once per day on days 1 & 14

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 25 mg PO prior to [[Rituximab (Rituxan)]] 
*[[Acetaminophen (Tylenol)]] 650 mg PO prior to [[Rituximab (Rituxan)]]
*[[Dexamethasone (Decadron)]] 10 mg IV or PO prior to [[Rituximab (Rituxan)]]
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day on days 1 to 10 of cycle 1
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO twice per day three times per week, for 6 months past last dose of chemotherapy
*[[Acyclovir (Zovirax)]] 400 mg PO three times per day, for 6 months past last dose of chemotherapy
*[[Filgrastim (Neupogen)]] or [[Pegfilgrastim (Neulasta)]] 24 hours after chemo (details not provided)

'''28-day cycles for 6 cycles'''
====Subsequent treatment====
*[[#Rituximab_monotherapy_2|Indefinite rituximab maintenance]]

===Variant #4, 40/250/375-500, oral FC {{#subobject:e5ab00|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30235-1/fulltext Dartigeas et al. 2017 (CLL 2007 SA)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> PO once per day on days 1 to 3
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1, then 500 mg/m<sup>2</sup> IV once on day 14
**Cycle 2: 500 mg/m<sup>2</sup> IV once per day on days 1 & 14
**Cycles 3 & 4: 500 mg/m<sup>2</sup> IV once on day 1

'''1-month cycle for 4 cycles'''
====Subsequent treatment====
*[[#Rituximab_monotherapy_2|Rituximab]] maintenance versus [[#Observation_2|observation]]

===Variant #5, 25/250/375 {{#subobject:6dc0af|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.21882/full Tam et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV over 15 to 30 minutes once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV over 15 to 30 minutes once per day on days 1 to 3
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 6 cycles or "attainment of maximum response"'''

===Variant #6, 24/150/375-500, oral FC {{#subobject:df045c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nature.com/leu/journal/v31/n10/full/leu201765a.html Munir et al. 2017 (ADMIRE)]
|style="background-color:#1a9851"|Randomized Phase IIB (C)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#R-FCM|FCM-R]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nature.com/leu/journal/v31/n11/full/leu201796a.html Howard et al. 2017 (ARCTIC)]
|style="background-color:#1a9851"|Randomized Phase IIB (C)
|FCM-miniR
| style="background-color:#1a9850" |Superior CR rate
|-
|}
''Note: in contrast to other variants, FC is given over 5 days not 3.''
====Chemotherapy====
*[[Fludarabine (Fludara)]] 24 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Cyclophosphamide (Cytoxan)]] 150 mg/m<sup>2</sup>/day PO on days 1 to 5
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 6 cycles'''

===References===
# Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4079-88. Epub 2005 Mar 14. [http://jco.ascopubs.org/content/23/18/4079.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15767648 PubMed]
## '''Update:''' Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15;112(4):975-80. Epub 2008 Apr 14. [http://www.bloodjournal.org/content/112/4/975.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952498/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18411418 PubMed]
## '''Update and Subgroup Analysis:''' Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016 Jan 21;127(3):303-9. Epub 2015 Oct 22. [http://www.bloodjournal.org/content/127/3/303.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760129/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26492934 PubMed]
# Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, Carney D, Seymour JF. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer. 2006 Jun 1;106(11):2412-20. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.21882/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16649223 PubMed]
# Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Feb 1;27(4):498-503. Epub 2008 Dec 15. [http://jco.ascopubs.org/content/27/4/498.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19075274 PubMed]
## '''Update:''' Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, Pietragallo L, Sulecki M, Tarhini A, Boyiadzis M. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012 Mar 29;119(13):3184-5. [http://www.bloodjournal.org/content/119/13/3184.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22461474 PubMed]
<!-- # '''Abstract:''' Hallek, Michael, Fingerle-Rowson, Guenter, Fink, Anna-Maria, Busch, Raymonde, Mayer, Jiri, Hensel, Manfred, Hopfinger, Georg, Hess, Georg, von Gruenhagen, Ulrich, Bergmann, Manuela A., Catalano, John, Zinzano, Pier Luigi, Cappio, Federico Caligaris, Seymour, John F, Berrebi, Alain, Jaeger, Ulrich, Cazin, Bruno, Trneny, Marek, Westermann, Anne, Wendtner, Clemens-Martin, Eichhorst, Barbara F., Staib, Peter, Boettcher, Sebastian, Ritgen, Matthias, Mendila, Myriam, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Fischer, Kirsten
First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.
ASH Annual Meeting Abstracts 2009 114: 535 [http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/535 link to abstract] -->
# '''GCLLSG CLL8:''' Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164-74. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961381-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20888994 PubMed]
## '''Update:''' Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14;127(2):208-15. Epub 2015 Oct 20. [http://www.bloodjournal.org/content/127/2/208.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26486789 PubMed]
## '''HRQoL analysis:''' Kutsch N, Busch R, Bahlo J, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Wendtner CM, Maria Fink A, Fischer K, Hallek M, Eichhorst B. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Feb;58(2):399-407. Epub 2016 Jun 29. [http://www.tandfonline.com/doi/full/10.1080/10428194.2016.1190966 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27357445 PubMed]
<!-- # '''Abstract:''' Lepretre S, Aurran T, Mahe B, Cazin B, Tournihlac O, Maisonneuve H, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du Sang" (GOELAMS) : CLL2007FMP (for fit medically patients). Blood 2009;114:538. [http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/538?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=CLL2007FMP&searchid=1&FIRSTINDEX=0&volume=114&issue=22&resourcetype=HWCIT link to abstract] -->
# Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10. Epub 2012 Feb 14. [http://www.bloodjournal.org/content/119/22/5104.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22337714 PubMed]
# '''Abstract:''' Carmen D Schweighofer, MD, Florence Cymbalista, MD, Carolin Müller, MD, Raymonde Busch, PhD, Raphael Porcher, PhD, Petra Langerbeins, MD, Bruno Cazin, MD, Anna-Maria Fink, MD, Brigitte Dreyfus, MD, Stefan Ibach, Stéphane Leprêtre, MD, Kirsten Fischer, MD, Ursula Vehling-Kaiser, MD, Barbara Eichhorst, MD, Manuela A. Bergmann, MD, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Veronique Leblond, MD, Michael Hallek, MD, and Vincent Levy, MD, PhD. Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial. 2013 ASH Annual Symposium abstract 524 [http://www.bloodjournal.org/content/122/21/524 link to abstract]
# Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014 Nov;167(4):466-77. Epub 2014 Aug 8. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13061/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25130401 PubMed]
<!-- # '''Abstract:''' Barbara Eichhorst, MD, Anna-Maria Fink, MD, Raymonde Busch, PhD, Elisabeth Lange, MD, Hubert Köppler, Prof. Dr., Michael Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, MD, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Marek Trneny, MD, Ph.D., Prof, Kirsten Fischer, MD, Hartmut Döhner, MD, Michael Kneba, MD, Clemens Wendtner, MD, Wolfram Klapper, Karl-Anton Kreuzer, Dr. med., Stephan Stilgenbauer, MD, Sebastian Böttcher, MD, and Michael Hallek, MD. Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG). 2013 ASH Annual Symposium abstract 526 [http://www.bloodjournal.org/content/122/21/526 link to abstract] -->
# '''GCLLSG CLL10:''' Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. Epub 2016 May 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30051-1/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27216274 PubMed]
# '''ADMIRE:''' Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M, Bloor A, Pettitt A, Fegan C, Blundell J, Gribben JG, Phillips D, Hillmen P. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia. 2017 Oct;31(10):2085-2093. Epub 2017 Apr 20. [https://www.nature.com/leu/journal/v31/n10/full/leu201765a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28216660 PubMed]
# '''ARCTIC:''' Howard DR, Munir T, McParland L, Rawstron AC, Milligan D, Schuh A, Hockaday A, Allsup DJ, Marshall S, Duncombe AS, O'Dwyer JL, Smith AF, Longo R, Varghese A, Hillmen P. Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia. 2017 Nov;31(11):2416-2425. Epub 2017 Mar 24. [https://www.nature.com/leu/journal/v31/n11/full/leu201796a.html link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28336937 PubMed]
# Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO). Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018 Feb;5(2):e82-e94. Epub 2017 Dec 20. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30235-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29275118 PubMed]

==Fludarabine & Alemtuzumab {{#subobject:29bf48|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:201b46|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70242-X/fulltext Elter et al. 2011 (CAM 314)]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Fludarabine_monotherapy|Fludarabine]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]]
*[[Alemtuzumab (Campath)]]

'''28-day cycle for up to 6 cycles'''

===References===
# '''CAM 314:''' Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, Kyrcz-Krzemień S, Vatutin M, Wu J, Sirard C, Hallek M, Engert A. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011 Dec;12(13):1204-13. Epub 2011 Oct 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70242-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21992852 PubMed]

==Ibrutinib monotherapy {{#subobject:8c370d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9887c1|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70513-8/fulltext O'Brien et al. 2013 (PCYC-1102)]
|style="background-color:#91cf61"|Phase Ib/II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71182-9/fulltext Farooqui et al. 2014 (NHLBI 12-H-0035)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722809/ Burger et al. 2015 (RESONATE-2)]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Chlorambucil_monotherapy|Chlorambucil]]
| style="background-color:#91cf60" |Seems to have superior OS (*)
|-
|[http://www.bloodjournal.org/content/126/23/2934 Langerbeins et al. 2015 (CLL12)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Placebo]]
|TBD
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1812836 Woyach et al. 2018 (Alliance A041202)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|[[#BR|BR]]
| style="background-color:#1a9850" |Superior PFS
|-
|Ibrutinib & Rituximab
| style="background-color:#ffffbf" |Seems not superior
|-
|}
'''''PCYC-1102''' was intended for elderly patients. Although both 420 mg and 840 mg doses were planned, the 840 mg cohort was closed due to findings of comparable efficacy in other studies. '''NHLBI 12-H-0035''' was intended for patients with p.TP53 aberrations. '''RESONATE-2''' was intended for patients older than 65 years. '''CLL12''' was intended for patients with asymptomatic [[#Binet_staging_.281981.29|Binet stage A]] CLL. Reported efficacy for RESONATE-2 is based on the 2018 update.''
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day

'''28-day cycles'''

===References===
# '''PCYC-1102:''' O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014 Jan;15(1):48-58. Epub 2013 Dec 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70513-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134524/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24332241 PubMed]
## '''Update:''' Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015 Apr 16;125(16):2497-506. Epub 2015 Feb 19. [http://www.bloodjournal.org/content/125/16/2497 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400288/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25700432 PubMed]
## '''Update:''' O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018 Apr 26;131(17):1910-1919. Epub 2018 Feb 2. [http://www.bloodjournal.org/content/131/17/1910.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29437592 PubMed]
# '''NHLBI 12-H-0035:''' Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015 Feb;16(2):169-76. Epub 2014 Dec 31. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71182-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342187/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25555420 PubMed]
# '''RESONATE-2:''' Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015 Dec 17;373(25):2425-37. Epub 2015 Dec 6. [https://www.nejm.org/doi/full/10.1056/NEJMoa1509388 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722809/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26639149 PubMed]
## '''Update:''' Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 Sep;103(9):1502-1510. Epub 2018 Jun 7. [http://www.haematologica.org/content/103/9/1502 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119145/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29880603 PubMed]
# '''Abstract:''' Petra Langerbeins, MD, Jasmin Bahlo, Christina Rhein, Paula Cramer, MD, Anna-Maria Fink, MD, Natali Pflug, MD, Julia von Tresckow, MD, Stephan Stilgenbauer, MD, Karl-Anton Kreuzer, Michael J. Eckart, MD, Ursula Vehling-Kaiser, MD, Rudolf Schlag, MD, Christina Balser, MD, Lothar Müller, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD and Michael Hallek, MD. Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. ASH Annual Meeting 2015 Abstract 2934. [http://www.bloodjournal.org/content/126/23/2934 link to abstract]
# '''Alliance A041202:''' Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 Dec 27;379(26):2517-2528. Epub 2018 Dec 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1812836 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30501481 PubMed]

==Ibrutinib & Obinutuzumab {{#subobject:7bb15f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e7072b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30788-5/fulltext Moreno et al. 2018 (iLLUMINATE)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Chlorambucil_.26_Obinutuzumab|G-Clb]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day
*[[Obinutuzumab (Gazyva)]] as follows:
**Cycle 1: 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once per day on days 8 & 15
**Cycles 2 to 6: 1000 mg IV once on day 1

'''28-day cycles'''
===References===
# '''iLLUMINATE:''' Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2018 Nov 30. [Epub ahead of print] [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30788-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30522969 PubMed]

==Obinutuzumab monotherapy {{#subobject:f0a8d4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1, standard-dose (1000 mg) {{#subobject:f89f3a|Variant=1}}=== 
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705612/ Byrd et al. 2015]
|style="background-color:#1a9851"|Randomized Phase II (C)
|High-dose obinutuzumab
|style="background-color:#fee08b"|Might have inferior ORR rate
|-
|}
====Chemotherapy====
*[[Obinutuzumab (Gazyva)]] as follows:
**Cycle 1: 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once per day on days 8 & 15 
**Cycle 2 onwards: 1000 mg IV once on day 1

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 650 to 1000 mg PO 30 to 60 minutes prior to each infusion
*[[:Category:Antihistamines|Antihistamine]] "such as" [[Diphenhydramine (Benadryl)]] 50 to 100 mg PO 30 to 60 minutes prior to each infusion
*[[Prednisolone (Millipred)]] 100 mg "or equivalent" IV before each of the first three infusions, afterwards at the discretion of treating physician

'''21-day cycle up to 8 cycles'''

===Variant #2, high-dose (2000 mg) {{#subobject:6ca538|Variant=1}}=== 
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705612/ Byrd et al. 2015]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Standard-dose obinutuzumab
|style="background-color:#d9ef8b"|Might have superior ORR rate
|-
|}
====Chemotherapy====
*[[Obinutuzumab (Gazyva)]] as follows:
**Cycle 1: either of the following:
***100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once on day 3, then 2000 mg IV once per day on days 8 & 15 
***100 mg IV once on day 1, then 1900 mg IV once on day 2, then 2000 mg IV once per day on days 8 & 15 
**Cycle 2 onwards: 2000 mg IV once on day 1

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 650 to 1000 mg PO 30 to 60 minutes prior to each infusion
*[[:Category:Antihistamines|Antihistamine]] "such as" [[Diphenhydramine (Benadryl)]] 50 to 100 mg PO 30 to 60 minutes prior to each infusion
*[[Prednisolone (Millipred)]] 100 mg "or equivalent" IV before each of the first three infusions, afterwards at the discretion of treating physician

'''21-day cycle up to 8 cycles'''

===References===
# Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J, Sharman JP. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016 Jan 7;127(1):79-86. Epub 2015 Oct 15. [http://www.bloodjournal.org/content/127/1/79.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705612/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26472752 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2 |[https://www.nejm.org/doi/full/10.1056/NEJM199805213382104 Dighiero et al. 1998 (FRE-CLL-85)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Chlorambucil_monotherapy|Chlorambucil]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|2. [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Chlorambucil_.26_Prednisone|Chlorambucil & Prednisone]]
|style="background-color:#d73027"|Inferior PFS
|-
|[http://www.bloodjournal.org/content/122/21/4127 Bergmann et al. 2013 (GCLLSG CLL1)]
|style="background-color:#1a9851"|Phase III (C)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Fludarabine_monotherapy|Fludarabine]]
|style="background-color:#d73027"|Inferior PFS
|-
|[http://www.bloodjournal.org/content/122/21/524 Schweighofer et al. 2013 (GCLLSG CLL7)]
|style="background-color:#1a9851"|Phase III (C)
|[[#FCR|FCR]]
|style="background-color:#d73027"|Inferior EFS
|-
|[http://www.bloodjournal.org/content/126/23/2934 Langerbeins et al. 2015 (CLL12)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Ibrutinib_monotherapy|Ibrutinib]]
|TBD
|-
|}

''No active treatment, also known as "watchful waiting".''

===References===
# '''FRE-CLL-85:''' Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL, Travade P. Chlorambucil in indolent chronic lymphocytic leukemia: French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998 May 21;338(21):1506-14. [https://www.nejm.org/doi/full/10.1056/NEJM199805213382104 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9593789 PubMed]
# '''Abstract:''' Manuela A. Bergmann, MD, Raymonde Busch, PhD, Barbara Eichhorst, MD, Andreas Buehler, MD, Norbert Fischer, MD, Michael J Eckart, MD, Ursula Vehling-Kaiser, MD, Ulrich Jäger, MD, Georg Hopfinger, MD, Clemens Wendtner, MD, Kirsten Fischer, MD, Bertold Emmerich, MD, Hartmut Döhner, MD, Michael Hallek, M.D. Ph.D. and Stephan Stilgenbauer, MD. Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG). Blood 2013 122:4127. [http://www.bloodjournal.org/content/122/21/4127 link to abstract]
# '''Abstract:''' Carmen D Schweighofer, MD, Florence Cymbalista, MD, Carolin Müller, MD, Raymonde Busch, PhD, Raphael Porcher, PhD, Petra Langerbeins, MD, Bruno Cazin, MD, Anna-Maria Fink, MD, Brigitte Dreyfus, MD, Stefan Ibach, Stéphane Leprêtre, MD, Kirsten Fischer, MD, Ursula Vehling-Kaiser, MD, Barbara Eichhorst, MD, Manuela A. Bergmann, MD, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Veronique Leblond, MD, Michael Hallek, MD, and Vincent Levy, MD, PhD. Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial. 2013 ASH Annual Symposium abstract 524 [http://www.bloodjournal.org/content/122/21/524 link to abstract]
# '''Abstract:''' Petra Langerbeins, MD, Jasmin Bahlo, Christina Rhein, Paula Cramer, MD, Anna-Maria Fink, MD, Natali Pflug, MD, Julia von Tresckow, MD, Stephan Stilgenbauer, MD, Karl-Anton Kreuzer, Michael J. Eckart, MD, Ursula Vehling-Kaiser, MD, Rudolf Schlag, MD, Christina Balser, MD, Lothar Müller, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD and Michael Hallek, MD. Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. ASH Annual Meeting 2015 Abstract 2934. [http://www.bloodjournal.org/content/126/23/2934 link to abstract]



=First-line therapy, non-randomized or retrospective data=

==Alemtuzumab & Methylprednisolone {{#subobject:29fd75|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:14ff47|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.35.9695 Pettitt et al. 2012 (NCRI CLL206)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Alemtuzumab (Campath)]]
*[[Methylprednisolone (Solumedrol)]] 

'''16 week course'''

===References===
# '''NCRI CLL206:''' Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012 May 10;30(14):1647-55. Epub 2012 Apr 9. [http://ascopubs.org/doi/full/10.1200/JCO.2011.35.9695 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22493413 PubMed]

==Bendamustine & Obinutuzumab {{#subobject:e26569|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
G-B: '''<u>G</u>'''azyva (Obinutuzumab), '''<u>B</u>'''endamustine
===Regimen {{#subobject:c1bbd2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416529/ Brown et al. 2015 (GALTON)]
|style="background-color:#91cf61"|Phase 1b, 20 pts
| style="background-color:#f7fcfd" |ORR: 90%
|-
|}
====Chemotherapy====
*[[Obinutuzumab (Gazyva)]] as follows:
**Cycle 1: 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once on days 8 & 15
**Cycles 2 to 6: 1000 mg IV once on day 1
*[[Bendamustine]] as follows:
**Cycle 1: 90 mg/m<sup>2</sup> IV once per day on days 2 & 3
**Cycles 2 to 6: 90 mg/m<sup>2</sup> IV once per day on days 1 &2

====Supportive medications====
*[[Acetaminophen (Tylenol)]] (dose not specified) prior to each [[Obinutuzumab (Gazyva)]] infusion
*[[:Category:Antihistamines|Antihistamine]] e.g. [[Diphenhydramine (Benadryl)]] prior to each [[Obinutuzumab (Gazyva)]] infusion
*[[:Category:Steroids|Highly potent corticosteroid]] (e.g. [[Prednisolone (Millipred)]] 100 mg IV) before first [[Obinutuzumab (Gazyva)]] infusion 
*[[Allopurinol (Zyloprim)]] or [[Rasburicase (Elitek)]] recommended for tumor lysis syndrome prophylaxis
*[[:Category:PCP_prophylaxis|PCP prophylaxis]] recommended
*[[:Category:Antivirals|Antiviral prophylaxis]] recommended

'''28-day cycle for 6 cycles'''

===References===
<!-- Presented at the 55th annual meeting of the American Society of Hematology, New Orleans, LA, December 9, 2013. -->
# '''GALTON:''' Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30;125(18):2779-85. Epub 2015 Mar 13. [http://www.bloodjournal.org/content/125/18/2779.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416529/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25769620 PubMed]

==CFAR {{#subobject:30ac6b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CFAR: '''<u>C</u>'''yclophosphamide, '''<u>F</u>'''ludarabine, '''<u>A</u>'''lemtuzumab, '''<u>R</u>'''ituximab
===Regimen {{#subobject:8db0af|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081295/ Parikh et al. 2011]
|style="background-color:#91cf61"|Phase II
| style="background-color:#f7fcfd" |ORR: 92%
|-
|}
''Note that the doses of cyclophosphamide and fludarabine are lower than in the r/r CFAR regimen.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV once per day on days 3 to 5
*[[Fludarabine (Fludara)]] 20 mg/m<sup>2</sup> IV once per day on days 3 to 5
*[[Alemtuzumab (Campath)]] 30 mg IV once per day on days 1, 3, 5
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 2
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 2

====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 6
*[[Acetaminophen (Tylenol)]] 500 mg PO once prior to each [[Rituximab (Rituxan)]]/[[Alemtuzumab (Campath)]]
*[[Diphenhydramine (Benadryl)]] 25 to 50 mg IV or PO once prior to each [[Rituximab (Rituxan)]]/[[Alemtuzumab (Campath)]]
*[[Hydrocortisone (Cortef)]] 100 mg IV once prior to each [[Rituximab (Rituxan)]]/[[Alemtuzumab (Campath)]]
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day for at least days 1 to 7 of cycle 1
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO once per day during treatment and for at least 3 to 6 months after last course
*Antiviral prophylaxis with ONE of the following:
**[[Valacyclovir (Valtrex)]] 500 mg PO once per day during treatment and for at least 3 to 6 months after last course
**OR [[Valganciclovir (Valcyte)]] 450 mg PO twice per day during treatment and for at least 3 to 6 months after last course

'''28-day cycle for 6 cycles'''

===References===
# Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011 Aug 25;118(8):2062-8. Epub 2011 Jul 12. [http://www.bloodjournal.org/content/118/8/2062.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081295/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21750315 PubMed]

==G-FC {{#subobject:b5592a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

G-FC: '''<u>G</u>'''azyva (Obinutuzumab), '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide

===Regimen {{#subobject:8a0232|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416529/ Brown et al. 2015 (GALTON)]
|style="background-color:#91cf61"|Non-randomized
|-
|}
====Chemotherapy====
*[[Obinutuzumab (Gazyva)]] as follows:
**Cycle 1: 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once on days 8 & 15
**Cycles 2 to 6: 1000 mg IV once on day 1
*[[Fludarabine (Fludara)]] as follows:
**Cycle 1: 25 mg/m<sup>2</sup> IV once per day on days 2 to 4
**Cycles 2 to 6: 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] as follows:
**Cycle 1: 250 mg/m<sup>2</sup> IV once per day on days 2 to 4
**Cycles 2 to 6: 250 mg/m<sup>2</sup> IV once per day on days 1 to 3

====Supportive medications====
*[[Acetaminophen (Tylenol)]] (dose not specified) prior to each [[Obinutuzumab (Gazyva)]] infusion
*[[:Category:Antihistamines|Antihistamine]] e.g. [[Diphenhydramine (Benadryl)]] prior to each [[Obinutuzumab (Gazyva)]] infusion
*[[:Category:Steroids|Highly potent corticosteroid]] (e.g. [[Prednisolone (Millipred)]] 100 mg IV) before first [[Obinutuzumab (Gazyva)]] infusion 
*[[Allopurinol (Zyloprim)]] or [[Rasburicase (Elitek)]] recommended for tumor lysis syndrome prophylaxis
*[[:Category:PCP_prophylaxis|PCP prophylaxis]] recommended
*[[:Category:Antivirals|Antiviral prophylaxis]] recommended

'''28-day cycle for 6 cycles'''

===References===
<!-- Presented at the 55th annual meeting of the American Society of Hematology, New Orleans, LA, December 9, 2013. -->
# '''GALTON:''' Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30;125(18):2779-85. Epub 2015 Mar 13. [http://www.bloodjournal.org/content/125/18/2779.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416529/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25769620 PubMed]

==HDMP-R {{#subobject:1c202|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
HDMP-R: '''<u>H</u>'''igh '''<u>D</u>'''ose, '''<u>M</u>'''ethyl'''<u>P</u>'''rednisolone & '''<u>R</u>'''ituximab

===Regimen {{#subobject:38a97d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761991/ Castro et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Methylprednisolone (Solumedrol)]] 1000 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 to 3
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> total divided over 2 days IV once on days 1 & 2, then 375 mg/m<sup>2</sup> IV once per day on days 8, 15, 22
**Cycles 2 & 3: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Cimetidine (Tagamet)]] as premedication for [[Methylprednisolone (Solumedrol)]]
*[[Acetaminophen (Tylenol)]] as premedication for [[Rituximab (Rituxan)]]
*[[Diphenhydramine (Benadryl)]] as premedication for [[Rituximab (Rituxan)]] 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] (or equivalent) prophylaxis during therapy and continuing for 2 months after treatment is complete
*[[Acyclovir (Zovirax)]] (or equivalent) prophylaxis during therapy and continuing for 2 months after treatment is complete
*[[Fluconazole (Diflucan)]] (or equivalent) prophylaxis during therapy and continuing for 2 months after treatment is complete
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day, started 3 days before the start of therapy and continued during treatment
*Patients with glucose greater than 200 on days of treatment received regular insulin SC sliding scale on days of treatment

'''28-day cycles for 3 cycles'''

===References===
# Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009 Oct;23(10):1779-89. Epub 2009 Aug 20. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761991/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19693094 PubMed]

==Idelalisib & Rituximab {{#subobject:7bacdd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:33cbcc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732760/ O'Brien et al. 2015 (Study 101-08)]
|style="background-color:#91cf61"|Phase II
|-
|}
''In a letter dated 3/21/2016, Gilead states that idelalisib should '''not''' be used for first line treatment of CLL.''
====Chemotherapy====
*[[Idelalisib (Zydelig)]] 150 mg PO twice per day for 48 weeks
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week for 8 weeks

'''48-week treatment; patients who had not progressed could continue on an extension study'''

===References===
<!-- # '''Abstract:''' Susan Mary O'Brien, Nicole Lamanna, Thomas J. Kipps, Ian Flinn, Andrew David Zelenetz, Jan Andreas Burger, Leanne Holes, David Michael Johnson, Jessie Gu, Roger D. Dansey, Ronald L. Dubowy, Steven E. Coutre. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kd) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol 31, 2013 (suppl; abstr 7005) [http://meetinglibrary.asco.org/content/117245-132 link to abstract] -->
# '''Study 101-08:''' O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17;126(25):2686-94. Epub 2015 Oct 15. [http://www.bloodjournal.org/content/126/25/2686.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732760/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26472751 PubMed]

==Lenalidomide & Rituximab {{#subobject:d71dfb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:5d17e2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067945/ James et al. 2014 (CRC014)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] with escalation in the absence of grade 2 or higher toxicities as follows:
**Cycle 1: 2.5 mg PO once per day on days 1 to 7, then 5 mg PO once per day on days 8 to 21
**Cycle 2: 5 mg PO once per day on days 1 to 21
**Subsequent cycles: 10 mg PO once per day on days 1 to 21
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on days 31 & 33
**Cycle 2: 375 mg/m<sup>2</sup> IV once per week on weeks 1 to 4
**Subsequent cycles: 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Allopurinol (Zyloprim)]] prior to starting [[Lenalidomide (Revlimid) | lenalidomide]] and with any dose escalation
*[[Aspirin]] 81 mg PO once per day

'''Cycle 1 is 35 days, then 28-day cycle up to 7 total cycles'''

===Variant #2 {{#subobject:82c08|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70455-3/fulltext Fowler et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}

''This combination was only studied in SLL (as opposed to CLL). Lenalidomide is dose-escalated to avoid tumor flare.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21, with an escalation of 5 mg/month to goal of 20 mg PO once per day
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 12 cycles'''

===References===
# '''CRC014:''' James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the Chronic Lymphocytic Leukemia Research Consortium. J Clin Oncol. 2014 Jul 1;32(19):2067-73. Epub 2014 May 27. [http://jco.ascopubs.org/content/32/19/2067.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067945/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24868031 PubMed]
<!--
# '''Abstract:''' N. H. Fowler, P. McLaughlin, F. B. Hagemeister, L. W. Kwak, M. A. Fanale, S. S. Neelapu, L. Fayad, R. Z. Orlowski, M. Wang, F. Samaniego. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 28:15s, 2010 (suppl; abstr 8036). 2010 ASCO Annual Meeting abstract 8036. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview==abst_detail_view&confID==74&abstractID==53803 link to abstract]
# '''Abstract:''' Nathan H Fowler, MD, Sattva S. Neelapu, MD, Fredrick B Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Robert Z. Orlowski, M.D., Ph.D., Michael Wang, M.D., Francesco Turturro, MD, Yasuhiro Oki, MD, Linda Catherine Lacerte, RN and Felipe Samaniego, MD, MPH. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. 2012 ASH Annual Meeting abstract 901. [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/901 link to abstract] -->
# Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov;15(12):1311-8. Epub 2014 Oct 15. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70455-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370362/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25439689 PubMed]

==O-FC {{#subobject:a1a5f0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
O-FC: '''<u>O</u>'''fatumumab, '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:e10e20|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916561/ Wierda et al. 2011 (407 Study)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 300 mg IV once on day 1 
**Cycles 2 to 6: 500 mg or 1000 mg IV once on day 1
*[[Fludarabine (Fludara)]] as follows:
**Cycle 1: 25 mg/m<sup>2</sup> IV once per day on days 2 to 4 
**Cycles 2 to 6: 25 mg/m<sup>2</sup> IV once per day on days 1 to 3 (note: there was ambiguity in Wierda et al. 2011 about whether both fludarabine and cyclophosphamide are given three days per cycle, or whether fludarabine is given once per cycle and only cyclophosphamide is given three days per cycle)
*[[Cyclophosphamide (Cytoxan)]] as follows:
**Cycle 1: 250 mg/m<sup>2</sup> IV once per day on days 2 to 4 
**Cycle 2 to 6: 250 mg/m<sup>2</sup> IV once per day on days 1 to 3

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg PO as premedication prior to [[Ofatumumab (Arzerra)]]
*[[Cetirizine (Zyrtec)]] 10 mg (or equivalent) PO as premedication prior to [[Ofatumumab (Arzerra)]]
*[[Prednisolone (Millipred)]] 100 mg ([[Steroid conversions|or equivalent]]) PO once before doses 1 & 2 of [[Ofatumumab (Arzerra)]], then reduced by physician discretion for later doses
*May be used at physician discretion:
**[[Allopurinol (Zyloprim)]] for tumor lysis syndrome prophylaxis
**Antiviral and PCP (Pneumocystis jiroveci pneumonia) prophylaxis
**Growth factor support

'''28-day cycle for 6 cycles'''

===References===
<!-- Data from this study were presented in part at the American Society of Hematology Annual Meeting, December 5-8, 2009, New Orleans, LA; the American Society of Clinical Oncology Annual Meeting, June 4-8, 2010, Chicago, IL; and the Congress of the European Hematology Association, June 10-13, 2010, Barcelona, Spain. -->
# Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA; 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011 Jun 16;117(24):6450-8. Epub 2011 Apr 15. [http://www.bloodjournal.org/content/117/24/6450.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916561/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21498674 PubMed]

==PCO {{#subobject:4eca93|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PCO: '''<u>P</u>'''entostatin, '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''fatumumab

===Regimen {{#subobject:75a1af|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894149/ Shanafelt et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666341/ Tedeschi et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30064-3/fulltext Strati et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pentostatin (Nipent)]] 2 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once on day 8
**Cycles 2 to 6: 1000 mg IV once on day 1

====Supportive medications====
*Best described in Shanafelt et al. 2013: 
*[[Methylprednisolone (Solumedrol)]] 80 mg IV once prior to each dose of [[Ofatumumab (Arzerra)]]
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day on days 1 to 14 of cycle 1
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] or similar for PJP prophylaxis for one year from start of treatment
*[[Valacyclovir (Valtrex)]] or similar for HSV prophylaxis for one year from start of treatment

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*Strati et al. 2016: [[#Ofatumumab_monotherapy|Ofatumumab]] consolidation

===References===
# Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer. 2013 Nov 1;119(21):3788-96. Epub 2013 Aug 6. Erratum in: Cancer. 2014 Mar 15;120(6):926. Dosage error in article text. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.28292 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894149/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23922059 PubMed]
# Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M; Rete Ematologica Lombarda–CLL Workgroup. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. Haematologica. 2015 Dec;100(12):e501-4. Epub 2015 Aug 20. [http://www.haematologica.org/content/100/12/e501.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666341/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26294723 PubMed]
# Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol. 2016 Sep;3(9):e407-14. Epub 2016 Aug 1. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30064-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27570087 PubMed]

==PCR {{#subobject:6b0b68|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PCR: '''<u>P</u>'''entostatin, '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''ituximab
===Variant #1 {{#subobject:90f7f7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278955/ Samaniego et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
''This regimen was specifically studied in SLL, not CLL.''
====Chemotherapy====
*[[Pentostatin (Nipent)]] 4 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Ondansetron (Zofran)]] 8 mg (route not specified) prior to chemotherapy
*[[Diphenhydramine (Benadryl)]] 25 mg (route not specified) prior to chemotherapy
*500 ml of 5% dextrose/one-half normal saline before and after each [[Pentostatin (Nipent)]] dose
*[[Filgrastim (Neupogen)]] at the discretion of the treating physician
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day on days 1 to 15 of cycle 1
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] once per day three days per week during and for 1 month following therapy
*[[Acyclovir (Zovirax)]] 400 mg PO twice per day during and for 1 month following therapy

'''21-day cycle for 6 cycles'''

===Variant #2 {{#subobject:90f7f6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1785105/ Kay et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.22662/full Shanafelt et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pentostatin (Nipent)]] 2 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 100 mg/m<sup>2</sup> IV once on day 1, then 375 mg/m<sup>2</sup> IV once per day on days 3 & 5 
**Cycles 2 to 6: 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*''Note: see references for details, as they differ by paper.''
*[[Filgrastim (Neupogen)]] once per day, starting on day 3 for up to 10 days or until ANC greater than 1000/uL for 2 straight days
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day on days 1 to 15 of cycle 1
*Prophylactic [[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] for 1 year
*Prophylactic [[Acyclovir (Zovirax)]] for 1 year

'''28-day cycle for 6 cycles'''

===References===
# Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007 Jan 15;109(2):405-11. Epub 2006 Sep 28. [http://www.bloodjournal.org/content/109/2/405.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1785105/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/17008537 PubMed]
# Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007 Jun 1;109(11):2291-8. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.22662/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17514743 PubMed]
# Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun;169(6):814-23. Epub 2015 Mar 31. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13367/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278955/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25828695 PubMed]

==Rituximab monotherapy {{#subobject:9f1176|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:c47e54|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ Williams et al. 2016 (RESORT substudy)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''This regimen was intended for patients with SLL.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week; initial infusion rate of 50 mg/H, then increased as tolerated by 50 mg/H every 30 minutes, to a maximum rate of 300 mg/H

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 650 mg PO 30 minutes prior to each dose of [[Rituximab (Rituxan)]]
*[[Diphenhydramine (Benadryl)]] 50 mg PO 30 minutes prior to each dose of [[Rituximab (Rituxan)]]

'''4-week course'''
====Subsequent treatment====
*Patients with PR/CR: [[#Rituximab_monotherapy_2|Indefinite rituximab]] versus [[#Rituximab_monotherapy_3|salvage rituximab at time of progression]]

===Variant #2 {{#subobject:d28cb1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/21/9/1746.long Hainsworth et al. 2003]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
**Optional alternate initial dosing for patients with WBC count greater than 100 x 10<sup>9</sup>/L: 100 mg IV once on day 1, with remainder of the 375 mg/m<sup>2</sup> dosage given on day 2
**''Initial infusion rate with first dose of rituximab: 50 mg/hr, then increased as tolerated by 50 mg/hr every 30 minutes to a maximum of 400 mg/hr. Infusion rate with subsequent doses of rituximab (if first dose tolerated): 100 mg/hr, then increased as tolerated by 100 mg/hr every 30 minutes to a maximum of 400 mg/hr.''

====Supportive medications====
*If WBC count greater than 50 x 10<sup>9</sup>/L or massive lymphadenopathy: [[Allopurinol (Zyloprim)]] 300 mg PO once per day, starting 3 days before the first dose of [[Rituximab (Rituxan)]]
*[[Acetaminophen (Tylenol)]] 650 mg PO once 30 minutes prior to [[Rituximab (Rituxan)]]
*[[Diphenhydramine (Benadryl)]] 50 mg IV once 30 minutes prior to [[Rituximab (Rituxan)]]
*One of the following, 30 minutes prior to [[Rituximab (Rituxan)]]:
**[[Cimetidine (Tagamet)]] 300 mg IV once
**[[Ranitidine (Zantac)]] 50 mg IV once

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*Patients with response or stable disease: [[#Rituximab_monotherapy_2|Rituximab maintenance]]

===References===
# Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA; Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003 May 1;21(9):1746-51. [http://jco.ascopubs.org/content/21/9/1746.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12721250 PubMed]
<!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. -->
# '''RESORT substudy:''' Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26970533 PubMed]

==Ruxolitinib monotherapy {{#subobject:a99c0d |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bc61db |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30194-6/fulltext Jain et al. 2017]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this was a trial focused on symptom control, not efficacy.''
====Chemotherapy====
*[[Ruxolitinib (Jakafi)]] 10 mg PO twice per day

===References===
# Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb;4(2):e67-e74. Epub 2017 Jan 11. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30194-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356368/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28089238 PubMed]

=Consolidation and/or maintenance after first-line therapy=

==Alemtuzumab monotherapy {{#subobject:004de9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 6-week course {{#subobject:831bd9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14342 Varghese et al. 2017 (NCRN CLL 207)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*Chemotherapy (details not specified)
====Chemotherapy====
*[[Alemtuzumab (Campath)]] 30 mg SC 3 times per week

'''6-week course'''

===Variant #2, 12-week course {{#subobject:36b1c2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nature.com/articles/2403354 Wendtner et al. 2004 (GCLLSG CLL4B)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_2|Observation]]
| style="background-color:#1a9850" |Superior PFS (*)
|-
|}
''Note: this study closed early due to high rates of infections in the experimental arm; efficacy is based on the 2009 update.''
====Preceding treatment====
*[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Fludarabine_monotherapy|F]] x 6 or [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#FC|FC]] x 6
====Chemotherapy====
*[[Alemtuzumab (Campath)]] as follows:
**Day 1: 3 mg SC once
**Day 2, if 3 mg dose is well tolerated: 10 mg SC once
**Day 3 onwards, if 10 mg dose is well tolerated: 30 mg SC once on day 3, then SC 3 times per week

'''12-week course'''

===References===
# '''GCLLSG CLL4B:''' Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Döhner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004 Jun;18(6):1093-101. [https://www.nature.com/articles/2403354 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15071604 PubMed]
## '''Update:''' Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009 Jan;144(1):95-8. Epub 2008 Oct 30. [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2008.07394.x link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19016732 PubMed]
# '''NCRN CLL207:''' Varghese AM, Howard DR, Pocock C, Rawstron AC, Follows G, McCarthy H, Dearden C, Fegan C, Milligan D, Smith AF, Gregory W, Hillmen P; NCRI CLL Sub-Group. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. Br J Haematol. 2017 Feb;176(4):573-582. Epub 2016 Dec 29. [https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14342 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28032335 PubMed]

==Lenalidomide monotherapy {{#subobject:7210a7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e227a0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30171-0/fulltext Fink et al. 2017 (GCLLSG CLLM1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_2|Observation]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Note that while the [https://clinicaltrials.gov/show/NCT01556776 NCT record] reports dose increases beyond 15 mg PO once per day, the abstract states that 15 mg PO once per day was the "target dose".''
====Preceding treatment====
*GCLLSG CLLM1: "Chemoimmunotherapy"
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] as follows:
**Cycle 1: 5 mg PO once per day
**If tolerated, Cycles 2 to 6: 10 mg PO once per day
**If tolerated, Cycle 7 onwards: 15 mg PO once per day

'''28-day cycles'''

===References===
# '''GCLLSG CLLM1:''' Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct;4(10):e475-e486. Epub 2017 Sep 12. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30171-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28916311 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nature.com/articles/2403354 Wendtner et al. 2004 (GCLLSG CLL4B)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Alemtuzumab_monotherapy_2|Alemtuzumab]]
|style="background-color:#d73027"|Inferior PFS (*)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668968/ Hochster et al. 2009 (ECOG E1496)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy_2|Rituximab]]
|style="background-color:#d73027"|Inferior PFS
|-
|[http://www.bloodjournal.org/content/117/5/1516.long Michallet et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|Autologous HSCT
|style="background-color:#d73027"|Inferior EFS
|-
|[http://www.bloodjournal.org/content/117/23/6109 Sutton et al. 2011 (Auto-LLC 2001)]
|style="background-color:#1a9851"|Phase III (C)
|Autologous HSCT
|style="background-color:#d73027"|Inferior EFS
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/ajh.23668/full Foà et al. 2014 (ML21445)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy_2|Rituximab]]
|style="background-color:#fee08b"|Might have inferior PFS
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30045-X/fulltext Greil et al. 2016 (AGMT CLL-8a)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy_2|Rituximab]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30171-0/fulltext Fink et al. 2017 (GCLLSG CLLM1)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Lenalidomide_monotherapy_2|Lenalidomide]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30235-1/fulltext Dartigeas et al. 2017 (CLL 2007 SA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy_2|Rituximab]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''No further treatment; used as a comparator arm. GCLLSG CLL4B closed early due to high rates of infections in the experimental arm; efficacy is based on the 2009 update.''
====Preceding treatment====
*GCLLSG CLL4B: [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Fludarabine_monotherapy|F]] x 6 versus [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#FC|FC]] x 6
*ECOG E1496: [[#CVP|CVP]]
*Auto-LLC 2001: mini-CHOP x 3, then [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#Fludarabine_monotherapy|F]] x 3
*ML21445: [[#Chlorambucil_.26_Rituximab|Clb-R]] 
*AGMT CLL-8a: "Rituximab-containing chemoimmunotherapy"
*GCLLSG CLLM1: "Chemoimmunotherapy"
*CLL 2007 SA: [[#FCR|FCR]] x 4
===References===
# '''GCLLSG CLL4B:''' Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Döhner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004 Jun;18(6):1093-101. [https://www.nature.com/articles/2403354 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15071604 PubMed]
## '''Update:''' Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009 Jan;144(1):95-8. Epub 2008 Oct 30. [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2008.07394.x link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19016732 PubMed]
# '''ECOG E1496:''' Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009 Apr 1;27(10):1607-14. Epub 2009 Mar 2. [http://jco.ascopubs.org/content/27/10/1607.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668968/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19255334 PubMed]
# Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D; EBMT Chronic Leukemia Working Party. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood. 2011 Feb 3;117(5):1516-21. Epub 2010 Nov 24. [http://www.bloodjournal.org/content/117/5/1516.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21106985 PubMed]
# '''Auto-LLC 2001:''' Sutton L, Chevret S, Tournilhac O, Diviné M, Leblond V, Corront B, Leprêtre S, Eghbali H, Van Den Neste E, Michallet M, Maloisel F, Bouabdallah K, Decaudin D, Berthou C, Brice P, Gonzalez H, Chapiro E, Radford-Weiss I, Leporrier N, Maloum K, Nguyen-Khac F, Davi F, Lejeune J, Merle-Béral H, Leporrier M; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Groupe Français d'étude de la Leucémie Lymphoïde Chronique (GFLLC). Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood. 2011 Jun 9;117(23):6109-19. Epub 2011 Mar 15. [http://www.bloodjournal.org/content/117/23/6109 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21406717 PubMed]
<!-- # '''Abstract:''' R Foa, A Alietti, A Guarini, S Ciolli, F Di Raimondo, G Del Poeta, F Lauria, F Forconi, A Cuneo, A Cortellezzi, F Nobile, V Callea, M Brugiatelli, M Massaia, S Molica, L Trentin, R Rizzi, G Specchia, L Orsucci, A Ambrosetti, M Montillo, L Zinzani, F Ferrara, F Morabito, M Mura, S Soriani, S Santangelo, M Marinelli, M De Propris, A Alietti, J Runggaldier. A PHASE II STUDY OF CHLORAMBUCIL+RITUXIMAB (CLB-R) FOLLOWED BY R MAINTENANCE VS OBSERVATION IN ELDERLY PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INDUCTION PHASE RESULTS. EHA Annual Meeting 2011, Abstract 0532 [http://www.ehaweb.org/congress-and-events/20th-congress/previous-congresses-2/abstract-book link to abstract book] -->
# '''ML21445:''' Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014 May;89(5):480-6. Epub 2014 Feb 18. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23668/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24415640 PubMed]
# '''AGMT CLL-8a:''' Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016 Jul;3(7):e317-29. Epub 2016 Jun 16. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30045-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27374465 PubMed]
# '''GCLLSG CLLM1:''' Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct;4(10):e475-e486. Epub 2017 Sep 12. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30171-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28916311 PubMed]
# '''CLL 2007 SA:''' Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO). Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018 Feb;5(2):e82-e94. Epub 2017 Dec 20. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30235-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29275118 PubMed]

==Ofatumumab monotherapy {{#subobject:4ff470|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:245061|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30064-3/fulltext Strati et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#PCO|PCO]] x 6
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] 1000 mg IV once on day 1

'''28-day cycle for 6 cycles'''

===References===
# Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol. 2016 Sep;3(9):e407-14. Epub 2016 Aug 1. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30064-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27570087 PubMed]

==Rituximab monotherapy {{#subobject:726c55|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 1 year {{#subobject:64c1ce|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/ajh.23668/full Foà et al. 2014 (ML21445)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_2|Observation]]
|style="background-color:#d9ef8b"|Might have superior PFS
|-
|}
====Preceding treatment====
*[[#Chlorambucil_.26_Rituximab|Clb-R]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 8 weeks

'''12 doses total'''

===Variant #2, 2 years, given q3mo {{#subobject:783b2c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/27/27/4578.long Bosch et al. 2009]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30045-X/fulltext Greil et al. 2016 (AGMT CLL-8a)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_2|Observation]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Preceding treatment====
*Bosch et al. 2009: [[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#R-FCM|R-FCM]]
*AGMT CLL-8a: "Rituximab-containing chemoimmunotherapy"
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 3 months

'''2 years total (8 doses)'''

===Variant #3, 2 years, given q8wk {{#subobject:14014d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30235-1/fulltext Dartigeas et al. 2017 (CLL 2007 SA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_2|Observation]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Note the higher dose used here.''
====Preceding treatment====
*[[#FCR|FCR]] x 4
====Chemotherapy====
*[[Rituximab (Rituxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''8-week cycle for up to 2 years'''

===Variant #4, 2 years, given q6mo {{#subobject:14014d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/21/9/1746.long Hainsworth et al. 2003]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668968/ Hochster et al. 2009 (ECOG E1496)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_2|Observation]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''ECOG E1496 included patients with SLL, but they were grouped into an "other" non-follicular lymphoma category.''
====Preceding treatment====
*Hainsworth et al. 2003: [[#Rituximab_monotherapy|Rituximab]] induction
*ECOG E1496: [[#CVP|CVP]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 650 mg PO once 30 minutes prior to [[Rituximab (Rituxan)]]
*[[Diphenhydramine (Benadryl)]] 50 mg IV once 30 minutes prior to [[Rituximab (Rituxan)]]
*One of the following, 30 minutes prior to [[Rituximab (Rituxan)]]:
**[[Cimetidine (Tagamet)]] 300 mg IV once
**[[Ranitidine (Zantac)]] 50 mg IV once

'''One course every 6 months (16 total doses)'''

===Variant #5, indefinite 375 mg/m<sup>2</sup> q3mo {{#subobject:d2473c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ Williams et al. 2016 (RESORT substudy)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy_3|Salvage rituximab]]
|style="background-color:#91cf60"|Seems to have superior TTTF
|-
|}
''Intended for patients with SLL.''
====Preceding treatment====
*[[#Rituximab_monotherapy|Rituximab]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 13 weeks

'''Continued indefinitely'''

===Variant #6, indefinite 500 mg/m<sup>2</sup> q3mo {{#subobject:0b3b08|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/27/4/498.long Foon et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#FCR|FCR-Lite]] x 6
====Chemotherapy====
*[[Rituximab (Rituxan)]] 500 mg/m<sup>2</sup> IV once every 3 months

'''Continued indefinitely'''

===References===
# Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA; Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003 May 1;21(9):1746-51. [http://jco.ascopubs.org/content/21/9/1746.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12721250 PubMed]
# Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Feb 1;27(4):498-503. Epub 2008 Dec 15. [http://jco.ascopubs.org/content/27/4/498.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19075274 PubMed]
## '''Update:''' Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, Pietragallo L, Sulecki M, Tarhini A, Boyiadzis M. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012 Mar 29;119(13):3184-5. [http://www.bloodjournal.org/content/119/13/3184.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22461474 PubMed]
<!-- Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL, and the Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL. -->
# '''ECOG E1496:''' Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009 Apr 1;27(10):1607-14. Epub 2009 Mar 2. [http://jco.ascopubs.org/content/27/10/1607.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668968/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19255334 PubMed]
<!-- Presented in part at the 43rd Annual Meeting of the American Society of Hematology, December 8-11, 2007, Atlanta, GA. -->
# Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 20;27(27):4578-84. Epub 2009 Aug 24. [http://jco.ascopubs.org/content/27/27/4578.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19704063 PubMed]
## '''Update:''' Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013 Dec 5;122(24):3951-9. Epub 2013 Oct 11. [http://www.bloodjournal.org/content/122/24/3951.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24124086 PubMed]
<!-- # '''Abstract:''' R Foa, A Alietti, A Guarini, S Ciolli, F Di Raimondo, G Del Poeta, F Lauria, F Forconi, A Cuneo, A Cortellezzi, F Nobile, V Callea, M Brugiatelli, M Massaia, S Molica, L Trentin, R Rizzi, G Specchia, L Orsucci, A Ambrosetti, M Montillo, L Zinzani, F Ferrara, F Morabito, M Mura, S Soriani, S Santangelo, M Marinelli, M De Propris, A Alietti, J Runggaldier. A PHASE II STUDY OF CHLORAMBUCIL+RITUXIMAB (CLB-R) FOLLOWED BY R MAINTENANCE VS OBSERVATION IN ELDERLY PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INDUCTION PHASE RESULTS. EHA Annual Meeting 2011, Abstract 0532 [http://www.ehaweb.org/congress-and-events/20th-congress/previous-congresses-2/abstract-book link to abstract book] -->
# '''ML21445:''' Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014 May;89(5):480-6. Epub 2014 Feb 18. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23668/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24415640 PubMed]
<!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. -->
# '''RESORT substudy:''' Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26970533 PubMed]
# '''AGMT CLL-8a:''' Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016 Jul;3(7):e317-29. Epub 2016 Jun 16. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30045-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27374465 PubMed]
# '''CLL 2007 SA:''' Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO). Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018 Feb;5(2):e82-e94. Epub 2017 Dec 20. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30235-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29275118 PubMed]
# '''PALG CLL4:''' Robak T, Błoński J, Skotnicki AB, Piotrowska M, Wróbel T, Rybka J, Kłoczko J, Bołkun Ł, Budziszewska BK, Walczak U, Uss A, Fidecka M, Smolewski P. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. Eur J Haematol. 2018 May;100(5):465-474. Epub 2018 Mar 22. [https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13042 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29427355 PubMed]

=Relapsed or refractory, randomized data=

==Bendamustine monotherapy {{#subobject:8973e4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1, 70 mg/m<sup>2</sup> {{#subobject:faab75|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324531/ Robak et al. 2016]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Bendamustine & Otlertuzumab
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|}
====Chemotherapy====
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 2

'''28-day cycle for 6 cycles'''

===Variant #2, 100 mg/m<sup>2</sup> {{#subobject:b1e65|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://link.springer.com/article/10.1007%2Fs00277-012-1660-6 Niederle et al. 2013]
|style="background-color:#1a9851"|Phase III (E)
|[[#Fludarabine_monotherapy|Fludarabine]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|}
====Chemotherapy====
*[[Bendamustine]] 100 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''28-day cycle for up to 8 cycles'''

===Variant #3, 120 mg/m<sup>2</sup> {{#subobject:3f29c2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/26/2/204.long Friedberg et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2916680/ Kahl et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bendamustine]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''21-day cycle for 6 to 8 (Kahl et al. 2010) or up to 12 (Friedberg et al. 2008) cycles'''

===References===
<!-- Presented in part at the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, Florida -->
# Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008 Jan 10;26(2):204-10. Erratum in: J Clin Oncol. 2008 Apr 10;26(11) 1911. [http://jco.ascopubs.org/content/26/2/204.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18182663 PubMed] 
<!-- Preliminary research findings from this study were presented at the 2007 American Society of Hematology Annual Meeting and Exposition, Atlanta, Georgia, December 8-11, 2007. -->
# Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010 Jan 1;116(1):106-14. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.24714/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2916680/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19890959 PubMed]
# '''Retrospective:''' Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. Ther Adv Hematol. 2013 Jun;4(3):157-71. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666446/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23730494 PubMed]
# Niederle N, Megdenberg D, Balleisen L, Heit W, Knauf W, Weiß J, Freier W, Hinke A, Ibach S, Eimermacher H. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol. 2013 May;92(5):653-60. Epub 2013 Jan 23. [http://link.springer.com/article/10.1007%2Fs00277-012-1660-6 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23340738 PubMed]
# Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2017 Feb;176(4):618-628. Epub 2016 Dec 15. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14464/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324531/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27977057 PubMed]

==BR {{#subobject:4d7261|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine & '''<u>R</u>'''ituximab
<br>R-B: '''<u>R</u>'''ituximab & '''<u>B</u>'''endamustine
===Regimen {{#subobject:39f839|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/29/26/3559.long Fischer et al. 2011]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00465-9/fulltext Chanan-Khan et al. 2015 (HELIOS)]
|style="background-color:#1a9851"|Phase III (C)
|[[#BR_.26_Ibrutinib|BR & Ibrutinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589180/ Zelenetz et al. 2017 (Tugela)]
|style="background-color:#1a9851"|Phase III (C)
|[[#BR_.26_Idelalisib|BR & Idelalisib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/ Michallet et al. 2018 (MABLE)]
| style="background-color:#1a9851"|Phase III (E)
|R-Clb
| style="background-color:#1a9850" |Superior CR rate
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1713976 Seymour et al. 2018 (MURANO)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Venetoclax_.26_Rituximab|Venetoclax & Rituximab]]
|style="background-color:#d73027"|Inferior OS
|-
|}
====Chemotherapy====
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 1 & 2
**HELIOS gave 1st cycle on days 2 & 3
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 0
***HELIOS gave on day 1
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 6 cycles based on response and toxicity'''

===References===
<!-- Presented in part at the 49th Annual Meeting of the American Society of Hematology, December 8-10, 2007, Atlanta, GA; and at the 50th Annual Meeting of the American Society of Hematology, December 6-9, 2008, San Francisco, CA. -->
# Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011 Sep 10;29(26):3559-66. Epub 2011 Aug 15. [http://jco.ascopubs.org/content/29/26/3559.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21844497 PubMed]
# '''Retrospective:''' Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. Ther Adv Hematol. 2013 Jun;4(3):157-71. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666446/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23730494 PubMed]
# '''HELIOS:''' Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-11. Epub 2015 Dec 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00465-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26655421 PubMed]
<!--
# '''Abstract:''' Andrew D Zelenetz, MD, PhD et al. Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. ASH 2015 Abstract LBA5 [https://ash.confex.com/ash/2015/webprogram/Paper87420.html link to abstract] -->
# '''Tugela:''' Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297-311. Epub 2017 Jan 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30671-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589180/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28139405 PubMed]
# '''MABLE:''' Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1. [http://www.haematologica.org/content/103/4/698 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29419437 PubMed]
# '''MURANO:''' Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 Mar 22;378(12):1107-1120. [https://www.nejm.org/doi/full/10.1056/NEJMoa1713976 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29562156 PubMed]
# '''Update:''' Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2018 Dec 3. [Epub ahead of print] [http://ascopubs.org/doi/full/10.1200/JCO.18.01580 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30523712 PubMed]

==BR & Ibrutinib {{#subobject:9861f9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR & Ibrutinib: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab, Ibrutinib
<br>IBR: '''<u>I</u>'''brutinib, '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab
===Regimen {{#subobject:ad1034|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424415/ Brown et al. 2015 (PCYC-1108)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00465-9/fulltext Chanan-Khan et al. 2015 (HELIOS)]
|style="background-color:#1a9851"|Phase III (E)
|[[#BR_2|BR]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
'''''PCYC-1108''' also evaluated FCR-ibrutinib (non-randomized) but accrual to that arm was extremely low and it was prematurely discontinued.''
====Chemotherapy====
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 1 & 2 
**HELIOS gave 1st cycle on days 2 & 3
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1 or split between days 1 & 2 (option described in '''PCYC-1108''')
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day

'''28-day cycle for up to 6 cycles (BR) and indefinitely (ibrutinib)'''

===References===
# '''PCYC-1108:''' Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 7;125(19):2915-22. Epub 2015 Mar 9. [http://www.bloodjournal.org/content/125/19/2915.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424415/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25755291 PubMed]
# '''HELIOS:''' Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-11. Epub 2015 Dec 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00465-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26655421 PubMed]

==BR & Idelalisib {{#subobject:025828|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR & Idelalisib: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab, Idelalisib
===Regimen {{#subobject:5c2b6f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589180/ Zelenetz et al. 2017 (Tugela)]
|style="background-color:#1a9851"|Phase III (E)
|[[#BR_2|BR]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Bendamustine]] as follows:
**Cycles 1 to 6: 70 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 0 
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1
*[[Idelalisib (Zydelig)]] 150 mg PO twice per day

'''28-day cycles'''

===References===
<!--
# '''Abstract:''' Andrew D Zelenetz, MD, PhD et al. Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. ASH 2015 Abstract LBA5 [https://ash.confex.com/ash/2015/webprogram/Paper87420.html link to abstract] -->
# '''Tugela:''' Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297-311. Epub 2017 Jan 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30671-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589180/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28139405 PubMed]

==Duvelisib monotherapy {{#subobject:4a9cdb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8e168d|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284216/ Flinn et al. 2018 (DUO)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Ofatumumab_monotherapy_2|Ofatumumab]]
|style="background-color:#1a9850" |Superior PFS 
|-
|}

====Chemotherapy====
*[[Duvelisib (Copiktra)]] 25 mg PO twice per day

'''Given for up to 18 cycles, progression of disease, or unacceptable toxicity'''
===References===
# Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018 Dec 6;132(23):2446-2455. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284216/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30287523 PubMed]

==FCR {{#subobject:b079e8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FCR: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''ituximab
<br>R-FC: '''<u>R</u>'''ituximab, '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide

===Variant #1 {{#subobject:b7f6d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13061/full Awan et al. 2014 (LUCID)]
|style="background-color:#1a9851"|Phase III (C)
|Lumiliximab + FCR
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] as follows:
**Cycle 1: 25 mg/m<sup>2</sup> IV over at least 10 to 30 minutes once per day on days 2 to 4 
**Cycles 2 to 6: 25 mg/m<sup>2</sup> IV over at least 10 to 30 minutes once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] as follows:
**Cycle 1: 250 mg/m<sup>2</sup> IV over at least 10 to 30 minutes once per day on days 2 to 4 
**Cycles 2 to 6: 250 mg/m<sup>2</sup> IV over at least 10 to 30 minutes once per day on days 1 to 3
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 50 mg/m<sup>2</sup> IV over 4 hours once on day 1, then 450 mg/m<sup>2</sup> IV once on day 3 
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Cotrimoxazole]] or an equivalent
*[[Acyclovir (Zovirax)]] 400 mg PO twice per day or an equivalent

'''28-day cycle for 6 cycles'''

===Variant #2 {{#subobject:9882b5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/28/10/1756.long Robak et al. 2010 (REACH)]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#FC_2|FC]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*''Note: varied according to reference.''
*[[Diphenhydramine (Benadryl)]] 25 mg IV once 30 minutes prior to [[Rituximab (Rituxan)]] 
*[[Acetaminophen (Tylenol)]] 650 mg PO once 30 minutes prior to [[Rituximab (Rituxan)]]
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day on days 1 to 7 of cycle 1
*Some patients received:
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO twice per week
**[[Valacyclovir (Valtrex)]] 500 mg PO once per day

'''28-day cycle for 6 cycles'''

===Variant #3 {{#subobject:fb9678|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/18/4070.full Wierda et al. 2005]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] as follows:
**Cycle 1: 25 mg/m<sup>2</sup> IV once per day on days 2 to 4 
**Cycles 2 to 6: 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] as follows:
**Cycle 1: 250 mg/m<sup>2</sup> IV once per day on days 2 to 4 
**Cycles 2 to 6: 250 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 25 to 50 mg PO once prior to [[Rituximab (Rituxan)]] 
*[[Acetaminophen (Tylenol)]] 650 mg PO once prior to [[Rituximab (Rituxan)]]
*[[Ondansetron (Zofran)]] 24 mg IV once prior to chemotherapy

'''28-day cycle for up to 6 cycles'''

===Variant #4 {{#subobject:49da52|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.21882/full Tam et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV over 15 to 30 minutes once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV over 15 to 30 minutes once per day on days 1 to 3
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 6 cycles or "attainment of maximum response"'''

===References===
# Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4070-8. Epub 2005 Mar 14. [http://jco.ascopubs.org/content/23/18/4070.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15767647 PubMed] 
## '''Update:''' Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011 Mar 17;117(11):3016-24. Epub 2011 Jan 18. [http://www.bloodjournal.org/content/117/11/3016.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123386/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21245487 PubMed]
# Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, Carney D, Seymour JF. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer. 2006 Jun 1;106(11):2412-20. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.21882/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16649223 PubMed]
<!-- Presented in part at the 50th Annual Meeting of the American Society of Hematology, December 6-9, 2008, San Francisco, CA. -->
# '''REACH:''' Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1756-65. Epub 2010 Mar 1. [http://jco.ascopubs.org/content/28/10/1756.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20194844 PubMed] content property of [http://hemonc.org HemOnc.org]
# '''LUCID:''' Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014 Nov;167(4):466-77. Epub 2014 Aug 8. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13061/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25130401 PubMed]

==Fludarabine monotherapy {{#subobject:1b68a3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d0644b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)91681-5/fulltext Johnson et al. 1996]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#CAP|CAP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://link.springer.com/article/10.1007%2Fs00277-012-1660-6 Niederle et al. 2013]
|style="background-color:#1a9851"|Phase III (C)
|[[#Bendamustine_monotherapy_2|Bendamustine]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because it was eventually used to establish this regimen as a standard comparator.''
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV once per day on days 1 to 5

'''28-day cycle for up to 6 to 12 cycles'''

===References===
# Johnson S, Smith AG, Löffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W; The French Cooperative Group on CLL. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet. 1996 May 25;347(9013):1432-8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)91681-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8676625 PubMed]
<!-- Presented in abstract form at the 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology, Berlin, Germany, September 20–24, 2009. -->
# Niederle N, Megdenberg D, Balleisen L, Heit W, Knauf W, Weiß J, Freier W, Hinke A, Ibach S, Eimermacher H. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol. 2013 May;92(5):653-60. Epub 2013 Jan 23. [http://link.springer.com/article/10.1007%2Fs00277-012-1660-6 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23340738 PubMed]

==Ibrutinib monotherapy {{#subobject:29205a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:acff1c|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772525/ Byrd et al. 2013 (PCYC-1102)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134521/ Byrd et al. 2014 (RESONATE)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Ofatumumab_monotherapy_2|Ofatumumab]]
|style="background-color:#1a9850"|Superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71182-9/fulltext Farooqui et al. 2014 (NHLBI 12-H-0035)]
|style="background-color:#ffffbe"|Phase II, <20 pts
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30212-1/fulltext O'Brien et al. 2016 (RESONATE-17)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.7504 Sharman et al. 2017 (GENUINE)]
|style="background-color:#1a9851"|Phase III (C)
|Ibrutinib & Ublituximab
|style="background-color:#d73027"|Inferior ORR
|-
|}
''Both 420 mg and 840 mg doses were investigated in '''PCYC-1102''': "the similar response in the two dose groups provide support for the use of the 420-mg dose of ibrutinib for relapsed CLL." The others used the 420 mg dose. '''RESONATE-17''' was intended for patients with 17p deletion.''
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day

'''Given indefinitely'''

===References===
# '''PCYC-1102:''' Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4;369(1):32-42. [https://www.nejm.org/doi/full/10.1056/NEJMoa1215637 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772525/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23782158 PubMed]
## '''Update:''' Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015 Apr 16;125(16):2497-506. Epub 2015 Feb 19. [http://www.bloodjournal.org/content/125/16/2497 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400288/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25700432 PubMed]
## '''Update:''' O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018 Apr 26;131(17):1910-1919. Epub 2018 Feb 2. [http://www.bloodjournal.org/content/131/17/1910.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29437592 PubMed]
<!-- # '''Abstract:''' John C. Byrd, Jennifer R. Brown, Susan Mary O'Brien, Jacqueline Claudia Barrientos, Neil E. Kay, Nishitha M. Reddy, Steven E. Coutre, Constantine Tam, Stephen P. Mulligan, Ulrich Jäger, Steve Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Maria Fardis, Jesse S. McGreivy, Fong Clow, Danelle Frances James, Peter Hillmen. Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. J Clin Oncol 32:5s, 2014 (suppl; abstr LBA7008) [http://abstracts.asco.org/144/AbstView_144_129571.html link to original abstract] -->
# '''RESONATE:''' Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; the RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213-23. Epub 2014 May 31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1400376 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134521/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24881631 PubMed]
<!-- ## '''Update: Abstract:''' John C. Byrd, Peter Hillmen, Susan Mary O'Brien, Jacqueline Claudia Barrientos, Nishitha M. Reddy, Steven Coutre, ... Constantine S. Tam, Stephen P. Mulligan, Ulrich Jäger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, John M. Pagel, Jan Andreas Burger, Jeffrey Alan Jones, Sandra Dai, Remus N. Vezan, Danelle Frances James, Jennifer R. Brown. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 7510-7510. [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.7510 link to abstract] -->
## '''Update:''' Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018 Jan;32(1):83-91. Epub 2017 Jun 8. [https://www.nature.com/articles/leu2017175 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28592889 PubMed]
# '''NHLBI 12-H-0035:''' Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015 Feb;16(2):169-76. Epub 2014 Dec 31. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71182-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342187/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25555420 PubMed]
# '''RESONATE-17:''' O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct;17(10):1409-1418. Epub 2016 Sep 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30212-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27637985 PubMed]
# '''Retrospective:''' Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016 Dec 22;128(25):2899-2908. [http://www.bloodjournal.org/content/128/25/2899 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179333/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27802969 PubMed]
# '''Abstract:''' Jeff Porter Sharman, Danielle M. Brander, Anthony R. Mato, Suman Kambhampati, John M. Burke, Frederick Lansigan, Marshall T. Schreeder, Scott D. Lunin, Nilanjan Ghosh, Alexander Zweibach, Mikhail Shtivelband, Patrick M. Travis, Jason Claud Chandler, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, and Ian Flinn. Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study. Journal of Clinical Oncology 2017 35:15_suppl, 7504-7504 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.7504 link to abstract]

==Idelalisib & Ofatumumab {{#subobject:c4f11b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7619d2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30019-4/fulltext Jones et al. 2017 (GS-US-312-0119)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Ofatumumab_monotherapy_2|Ofatumumab]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Idelalisib (Zydelig)]] 150 mg PO twice per day
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22 
**Cycle 2: 1000 mg IV once per day on days 1, 8, 15, 22 
**Cycles 3 to 6: 1000 mg IV once on day 1

'''28-day cycle for 6 cycles'''

===References===
# '''GS-US-312-0119:''' Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar;4(3):e114-e126. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30019-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28257752 PubMed]

==Idelalisib & Rituximab {{#subobject:353bcd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:2fb35e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365/ Furman et al. 2014 (Study 116)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Rituximab_monotherapy_3|Rituximab]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Idelalisib (Zydelig)]] 150 mg PO twice per day
*[[Rituximab (Rituxan)]] as follows:
**Week 1: 375 mg/m<sup>2</sup> IV once 
**Weeks 3 to 9: 500 mg/m<sup>2</sup> IV once every two weeks
**Weeks 13 to 21: 500 mg/m<sup>2</sup> IV once every four weeks

'''Rituximab is given for 8 total doses; idelalisib continues until progression, and can be increased to 300 mg PO twice per day at that point'''

===References===
# '''Study 116:''' Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007. Epub 2014 Jan 22. [https://www.nejm.org/doi/full/10.1056/NEJMoa1315226 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24450857 PubMed]

==Ofatumumab monotherapy {{#subobject:75bd7e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 2 cycles {{#subobject:e4b8d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13380/full Österborg et al. 2015 (GEN416)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Patients in this trial were fludarabine refractory and had previously received ofatumumab; this is a re-treatment trial.''
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] as follows: 
**Cycle 1: 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22 
**Cycle 2: 2000 mg IV once per day on days 1, 8, 15, 22 

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg PO once prior to each infusion
*[[Cetirizine (Zyrtec)]] (or equivalent) 10 mg PO once prior to each infusion
*[[Prednisolone (Millipred)]] 100 mg (or [[Steroid conversions|equivalent]]) PO once before infusions 1, 2, and 9 (question whether this was a typo), reduced or omitted if initial infusions well-tolerated

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*Patients with SD or better could proceed to [[#Ofatumumab_monotherapy_3|ofatumumab maintenance]]

===Variant #2, 6 cycles {{#subobject:d30c3f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/111/3/1094.long Coiffier et al. 2007]
|style="background-color:#91cf61"|Phase I/II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979101/ Wierda et al. 2010 (Hx-CD20-406)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134521/ Byrd et al. 2014 (RESONATE)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Ibrutinib_monotherapy_2|Ibrutinib]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30019-4/fulltext Jones et al. 2017 (GS-US-312-0119)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Idelalisib_.26_Ofatumumab|Idelalisib & Ofatumumab]]
|style="background-color:#d73027"|Inferior PFS
|-
|(DUO)
|style="background-color:#1a9851"|Phase III (C)
|[[#Duvelisib_monotherapy|Duvelisib]]
|See note
|-
|}
''Note: this regimen is sometimes described as 300 mg IV once on day 1, then 2000 mg IV once per week for 7 weeks, then 2000 mg IV once every 4 weeks for 16 weeks. We are not aware of any published results for DUO; we will add them when available. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22 
**Cycle 2: 2000 mg IV once per day on days 1, 8, 15, 22 
**Cycles 3 to 6: 2000 mg IV once on day 1

====Supportive medications====
*[[Prednisolone (Millipred)]] 100 mg (or [[Steroid conversions|equivalent]]) PO once before infusions 1, 2, and 9 (question whether this was a typo), reduced to lower doses if initial infusions well-tolerated

'''28-day cycle for 6 cycles'''

===Variant #3, 12 cycles {{#subobject:72f09e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
|-
|[http://www.bloodjournal.org/content/129/13/1876.long Ghia et al. 2017 (P07714)]
|style="background-color:#1a9851"|Phase III (C)
|Dinaciclib
|-
|}
''Note: this trial was terminated early and no statistical tests were performed; note also that cycle 3 is "skipped".''
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22 
**Cycle 2: 2000 mg IV once per day on days 1, 8, 15, 22 
**Cycle 3: no treatment
**Cycles 4 to 12: 2000 mg IV once on day 1

'''28-day cycle for 12 cycles'''

===References===
# Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008 Feb 1;111(3):1094-100. Epub 2007 Nov 14. [http://www.bloodjournal.org/content/111/3/1094.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18003886 PubMed]
<!-- # Wierda, W.G., Kipps, T.J., Mayer, J., Robak, T., Dyer, M.J.S., Furman, R.R., Hillmen, P., Stilgenbauer, S., Williams, C.D., Trneny, M., Cartron, G., Hernandez-Ilizaliturri, F.J., Padmanabhan, S., Chan, G.W., Gupta, I.V., Gorczyca, M.M., Davis, R.L., Losic, N., Lisby, S. & Österborg, A. (2010a) Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts), 116, Abstract 921. -->
# '''Hx-CD20-406:''' Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1749-55. Epub 2010 Mar 1. [http://jco.ascopubs.org/content/28/10/1749.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979101/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20194866 PubMed]
<!-- Presented in part as an oral presentation at the 52nd Annual Meeting of the American Society of Hematology, December 7, 2010, Orlando, FL; and as a poster presentation at the 15th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myelomas, February 17-20, 2011, Whistler, BC. -->
## '''Subgroup analysis:''' Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A; Hx-CD20-406 Study Investigators. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011 Nov 10;118(19):5126-9. Epub 2011 Aug 19. [http://www.bloodjournal.org/content/118/19/5126.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916553/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21856867 PubMed] 
## '''Update:''' Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG; Hx-CD20-406 Study Investigators. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Aug;100(8):e311-4. Epub 2015 Mar 13. [http://www.haematologica.org/content/100/8/e311.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004432/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25769539 PubMed]
<!-- # '''Abstract:''' John C. Byrd, Jennifer R. Brown, Susan Mary O'Brien, Jacqueline Claudia Barrientos, Neil E. Kay, Nishitha M. Reddy, Steven E. Coutre, Constantine Tam, Stephen P. Mulligan, Ulrich Jäger, Steve Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Maria Fardis, Jesse S. McGreivy, Fong Clow, Danelle Frances James, Peter Hillmen. Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. J Clin Oncol 32:5s, 2014 (suppl; abstr LBA7008) [http://abstracts.asco.org/144/AbstView_144_129571.html link to original abstract] -->
# '''RESONATE:''' Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; the RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213-23. Epub 2014 May 31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1400376 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134521/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24881631 PubMed]
<!-- ## '''Update: Abstract:''' John C. Byrd, Peter Hillmen, Susan Mary O'Brien, Jacqueline Claudia Barrientos, Nishitha M. Reddy, Steven Coutre, ... Constantine S. Tam, Stephen P. Mulligan, Ulrich Jäger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, John M. Pagel, Jan Andreas Burger, Jeffrey Alan Jones, Sandra Dai, Remus N. Vezan, Danelle Frances James, Jennifer R. Brown. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 7510-7510. [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.7510 link to abstract] -->
## '''Update:''' Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018 Jan;32(1):83-91. Epub 2017 Jun 8. [https://www.nature.com/articles/leu2017175 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28592889 PubMed]
# '''Retrospective:''' Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase 4, non--interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica. 2015 Apr;100(4):511-6. Epub 2015 Jan 16. [http://www.haematologica.org/content/100/4/511 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380724/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25596264 PubMed]
# '''GEN416:''' Österborg A, Wierda WG, Mayer J, Hess G, Hillmen P, Schetelig J, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Kozlowski P, Pfreundschuh M, Rizzi R, Spacek M, Phillips JL, Gupta IV, Williams V, Jewell RC, Nebot N, Lisby S, Dyer MJ. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2015 Jul;170(1):40-9. Epub 2015 Mar 30. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13380/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25825041 PubMed]
# '''GS-US-312-0119:''' Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar;4(3):e114-e126. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30019-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28257752 PubMed]
# '''P07714:''' Ghia P, Scarfò L, Perez S, Pathiraja K, Derosier M, Small K, McCrary Sisk C, Patton N. Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. Blood. 2017 Mar 30;129(13):1876-1878. Epub 2017 Jan 26. [http://www.bloodjournal.org/content/129/13/1876.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28126927 PubMed]
# '''DUO:''' [https://clinicaltrials.gov/ct2/show/NCT02004522 CT.gov record]

==O-FC {{#subobject:815d07|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
O-FC: '''<u>O</u>'''fatumumab, '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:f8f0ee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.tandfonline.com/doi/full/10.1080/10428194.2016.1233536 Robak et al. 2016 (COMPLEMENT 2)]
|style="background-color:#1a9851"|Phase III (E)
|[[Chronic_lymphocytic_leukemia_(CLL/SLL)_-_historical#FC_2|FC]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Note: dosing details were not available in the abstract; this is the dosing from [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916561/ Wierda et al. 2011].''
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 300 mg IV once on day 1 
**Cycles 2 to 6: 500 mg or 1000 mg IV once on day 1
*[[Fludarabine (Fludara)]] as follows:
**Cycle 1: 25 mg/m<sup>2</sup> IV once per day on days 2 to 4 
**Cycles 2 to 6: 25 mg/m<sup>2</sup> IV once per day on days 1 to 3 (note: there was ambiguity in Wierda et al. 2011 about whether both fludarabine and cyclophosphamide are given three days per cycle, or whether fludarabine is given once per cycle and only cyclophosphamide is given three days per cycle)
*[[Cyclophosphamide (Cytoxan)]] as follows:
**Cycle 1: 250 mg/m<sup>2</sup> IV once per day on days 2 to 4 
**Cycle 2 to 6: 250 mg/m<sup>2</sup> IV once per day on days 1 to 3

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg PO as premedication prior to [[Ofatumumab (Arzerra)]]
*[[Cetirizine (Zyrtec)]] 10 mg (or equivalent) PO as premedication prior to [[Ofatumumab (Arzerra)]]
*[[Prednisolone (Millipred)]] 100 mg ([[Steroid conversions|or equivalent]]) PO once before doses 1 & 2 of [[Ofatumumab (Arzerra)]], then reduced by physician discretion for later doses
*May be used at physician discretion:
**[[Allopurinol (Zyloprim)]] for tumor lysis syndrome prophylaxis
**Antiviral and PCP (Pneumocystis jiroveci pneumonia) prophylaxis
**Growth factor support

'''28-day cycle for 6 cycles'''

===References===
# Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, Loscertales J, Kryachok I, Kłoczko J, Rekhtman G, Homenda W, Błoński JZ, McKeown A, Gorczyca MM, Carey JL, Chang CN, Lisby S, Gupta IV, Grosicki S. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2017 May;58(5):1084-1093. Epub 2016 Oct 12. [http://www.tandfonline.com/doi/full/10.1080/10428194.2016.1233536 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27731748 PubMed]

==Rituximab monotherapy {{#subobject:5623dc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1, 4-week course {{#subobject:b7407a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/16/8/2825.long McLaughlin et al. 1998]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ Williams et al. 2016 (RESORT substudy)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Rituximab_monotherapy_2|Maintenance rituximab]]
|style="background-color:#fc8d59"|Seems to have inferior TTTF
|-
|}
====Preceding treatment====
*RESORT substudy: [[#Rituximab_monotherapy|Rituximab]], with progression
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''One course'''

===Variant #2, 8 doses {{#subobject:5ed834|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365/ Furman et al. 2014 (Study 116)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Idelalisib_.26_Rituximab_2|Idelalisib & Rituximab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on first dose, then 500 mg/m<sup>2</sup> IV once on subsequent doses

'''Given every two weeks for 5 doses then every three weeks for 3 doses for 8 total doses.'''

===References===
# McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. [http://jco.ascopubs.org/content/16/8/2825.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9704735 PubMed]
# '''Study 116:''' Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007. Epub 2014 Jan 22. [https://www.nejm.org/doi/full/10.1056/NEJMoa1315226 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24450857 PubMed]
<!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. -->
# '''RESORT substudy:''' Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26970533 PubMed]

==Venetoclax & Rituximab {{#subobject:68691a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VEN+R: '''<u>VEN</u>'''etoclax & '''<u>R</u>'''ituximab
===Regimen {{#subobject:4584a5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1713976 Seymour et al. 2018 (MURANO)]
|style="background-color:#1a9851"|Phase III (E)
|[[#BR_2|BR]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Venetoclax (Venclexta)]] as follows:
**Week 1: 20 mg PO once per day
**Week 2: 50 mg PO once per day
**Week 3: 100 mg PO once per day
**Week 4: 200 mg PO once per day
**Week 5 onwards: 400 mg PO once per day
*[[Rituximab (Rituxan)]] as follows:
**Week 6: 375 mg/m<sup>2</sup> IV once on day 1
**Weeks 10, 14, 18, 22, 26: 500 mg/m<sup>2</sup> IV once on day 1

'''Up to 2-year course'''
===References===
# '''MURANO:''' Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 Mar 22;378(12):1107-1120. [https://www.nejm.org/doi/full/10.1056/NEJMoa1713976 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29562156 PubMed]
# '''Update:''' Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2018 Dec 3. [Epub ahead of print] [http://ascopubs.org/doi/full/10.1200/JCO.18.01580 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30523712 PubMed]

=Relapsed or refractory, non-randomized or retrospective data=

==Acalabrutinib monotherapy {{#subobject:68ce71|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b52ef9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862586/ Byrd et al. 2015 (ACE-CL-001)]
|style="background-color:#91cf61"|Phase I/II
|ORR: 95%
|-
|}
''Note: this is the dose used in the expansion cohort.''
====Chemotherapy====
*[[Acalabrutinib (Calquence)]] 100 mg PO twice per day

'''Continued until progression or intolerance'''

===References===
# '''ACE-CL-001:''' Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):323-32. Epub 2015 Dec 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1509981 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862586/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26641137 PubMed]

==Alemtuzumab monotherapy {{#subobject:ab5318|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:132852|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/99/10/3554.full Keating et al. 2002]
|style="background-color:#91cf61"|Phase II
|-
|[http://jco.ascopubs.org/content/20/18/3891.long Rai et al. 2002]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Alemtuzumab (Campath)]] as follows:
**3 mg IV once per day, then increased as tolerated in terms of infusion reactions to 10 mg IV once per day, and then to 30 mg IV once per day
**Once 30 mg dose is tolerated: 30 mg IV over 2 hours, 3 times per week

====Supportive medications====
*''Note: see references for details, as they differ by paper.''
*[[Diphenhydramine (Benadryl)]] 50 mg PO once 30 minutes prior to [[Alemtuzumab (Campath)]] 
*[[Acetaminophen (Tylenol)]] 650 mg PO once 30 minutes prior to [[Alemtuzumab (Campath)]] 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO 3 times per week, starting on day 8, continuing at a minimum until 2 months after treatment is complete
*[[Famciclovir (Famvir)]] 250 mg PO twice per day, starting on day 8, continuing at a minimum until 2 months after treatment is complete

'''Up to 12 to 16 weeks of therapy;''' total course varies depending on reference

===Variant #2 {{#subobject:893a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/103/9/3278.long Lozanski et al. 2004]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Alemtuzumab (Campath)]] 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3, then 30 mg IV 3 days per week

====Supportive medications====
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] or [[Sargramostim (Leukine) | GM-CSF]] per institutional protocol
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO 3 times per week during therapy and continued for 6 months after treatment is complete
*[[Acyclovir (Zovirax)]] 800 mg PO three times per day during therapy and continued for 6 months after treatment is complete; similar medication can be used if intolerant of acyclovir 

'''12 weeks of therapy'''

===References===
# Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 May 15;99(10):3554-61. [http://www.bloodjournal.org/content/99/10/3554.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11986207 PubMed]
<!-- This work was presented in part at the Forty-Second Annual Meeting of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. -->
# Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002 Sep 15;20(18):3891-7. [http://jco.ascopubs.org/content/20/18/3891.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12228210 PubMed]
# Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas D, Grever MR, Byrd JC. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004 May 1;103(9):3278-81. Epub 2004 Jan 15. [http://www.bloodjournal.org/content/103/9/3278.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14726385 PubMed]

==Alemtuzumab & Rituximab {{#subobject:b3ab64|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ed4d6e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/101/9/3413.long Faderl et al. 2003]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Alemtuzumab (Campath)]] 3 mg IV once on day 1, 10 mg IV once on day 2, 30 mg IV once on day 3 of week 1, then 30 mg IV once per day on days 10, 12, 17, 19, 24, 26 (i.e. days 3 and 5 of weeks 2 to 4)
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
**For patients with WBC count greater than 50 x 10<sup>9</sup>/L, the first dose of [[Rituximab (Rituxan)]] was split into 100 mg/m<sup>2</sup> IV once on day 1 and 275 mg/m<sup>2</sup> IV once on day 2

====Supportive medications====
*Prophylactic [[Trimethoprim/Sulfamethoxazole (Bactrim DS)]], given during therapy and continuing at a minimum until 2 months after treatment is complete
*Prophylactic [[Valacyclovir (Valtrex)]] (or equivalent), given during therapy and continuing at a minimum until 2 months after treatment is complete

'''28-day cycle for 1 to 2 cycles depending on response and toxicity'''

===References===
# Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 1;101(9):3413-5. Epub 2003 Jan 9. [http://www.bloodjournal.org/content/101/9/3413.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12522009 Pubmed]

==Bendamustine & Ofatumumab {{#subobject:4eab04|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BendOfa: '''<u>Bend</u>'''amustine & '''<u>Ofa</u>'''tumumab

===Regimen {{#subobject:c1d63f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nature.com/leu/journal/v28/n3/full/leu2013334a.html Cortelezzi et al. 2013 (GIMEMA CLL0809)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#bfd3e6" |ORR: 72% (95% CI, 57–84%)
|-
|}
====Chemotherapy====
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once on day 7
**Cycle 2 onwards: 1000 mg IV once on day 1

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg PO prior to [[Ofatumumab (Arzerra)]]
*[[Diphenhydramine (Benadryl)]] 50 mg PO prior to [[Ofatumumab (Arzerra)]]
*[[Methylprednisolone (Solumedrol)]] 40 mg IV prior to [[Ofatumumab (Arzerra)]]
*[[Allopurinol (Zyloprim)]] or [[Rasburicase (Elitek)]] required for prophylaxis against TLS; dose not specified
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] required; dose not specified
*[[Acyclovir (Zovirax)]] required; dose not specified

'''28-day cycle up to 6 cycles'''

===References===
# '''GIMEMA CLL0809:''' Cortelezzi A, Sciumè M, Liberati AM, Vincenti D, Cuneo A, Reda G, Laurenti L, Zaja F, Marasca R, Chiarenza A, Gritti G, Orsucci L, Storti S, Angelucci E, Cascavilla N, Gobbi M, Mauro FR, Morabito F, Fabris S, Piciocchi A, Vignetti M, Neri A, Rossi D, Giannarelli D, Guarini A, Foà R. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA multicenter phase II trial. Leukemia. 2014 Mar;28(3):642-8. Epub 2013 Nov 13. [https://www.nature.com/leu/journal/v28/n3/full/leu2013334a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24220274 PubMed]

==CFAR {{#subobject:6cf406|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CFAR: '''<u>C</u>'''yclophosphamide, '''<u>F</u>'''ludarabine, '''<u>A</u>'''lemtuzumab, '''<u>R</u>'''ituximab

===Regimen {{#subobject:40c38d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123326/ Badoux et al. 2011]
|style="background-color:#91cf61"|Phase II
| style="background-color:#bfd3e6" |ORR: 65%
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV once per day on days 3 to 5
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV once per day on days 3 to 5
*[[Alemtuzumab (Campath)]] 30 mg IV once per day on days 1, 3, 5
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 2
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once on day 2

====Supportive medications====
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day on days 1 to 7 of cycle 1
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO twice per day
*Antiviral prophylaxis with:
**EITHER [[Valacyclovir (Valtrex)]] 500 mg PO once per day
**OR [[Valganciclovir (Valcyte)]] 450 mg PO twice per day
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 6

*At physician's discretion:
**[[Acetaminophen (Tylenol)]] 650 mg PO once 30 minutes prior to [[Rituximab (Rituxan)]]/[[Alemtuzumab (Campath)]]
**[[Diphenhydramine (Benadryl)]] 25 to 50 mg IV or PO once 30 minutes prior to [[Rituximab (Rituxan)]]/[[Alemtuzumab (Campath)]]
**[[Hydrocortisone (Cortef)]] 100 mg IV once 30 minutes prior to [[Alemtuzumab (Campath)]]

'''28-day cycle for 6 cycles'''

===References===
# Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011 Aug 25;118(8):2085-93. Epub 2011 Jun 13. [http://www.bloodjournal.org/content/118/8/2085.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123326/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21670470 PubMed]

==FluCam {{#subobject:29fdc1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FluCam: '''<u>Flu</u>'''darabine, '''<u>Cam</u>'''path
===Regimen {{#subobject:3a84a1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/28/7024.long Elter et al. 2005]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Alemtuzumab (Campath)]] as follows:
**Cycle 1: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3 
**Cycles 2 to 6: 30 mg IV once per day on days 1 to 3

====Supportive medications====
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS) | Trimethoprim/Sulfamethoxazole]] 960 mg (paper did not specify which component was 960 mg) PO once per day, started on day 1 and continued at least 2 months after treatment is complete 
*[[Valacyclovir (Valtrex)]] 500 mg PO twice per day, started on day 1 and continued at least 2 months after treatment is complete 
**If patients experienced CMV (cytomegalovirus) reactivation, valacyclovir was replaced by "oral or intravenous ganciclovir" 500 mg TID
*[[Fluconazole (Diflucan)]] 100 mg PO once per day, started if patients had evidence of fungal infection, continued until resolution
*[[Acetaminophen (Tylenol)]] 1000 mg PO once prior to first dose of [[Alemtuzumab (Campath)]], then with subsequent doses if clinically indicated
*[[Clemastine (Tavist)]] 2 mg IV once prior to first dose of [[Alemtuzumab (Campath)]], then with subsequent doses if clinically indicated
*[[Prednisone (Sterapred)]] 100 mg IV once prior to first dose of [[Alemtuzumab (Campath)]], then with subsequent doses if clinically indicated
*For patients with WBC count greater than 50 x 10<sup>9</sup>/L, bulky disease, or history of hyperuricemia: [[Allopurinol (Zyloprim)]] 300 mg PO once prior to first dose of [[Alemtuzumab (Campath)]], and used later if clinically indicated

'''28-day cycle for 6 cycles'''

===References===
# Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005 Oct 1;23(28):7024-31. Epub 2005 Sep 6. [http://jco.ascopubs.org/content/23/28/7024.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16145065 PubMed]

==Fludarabine & Prednisone {{#subobject:a00ad0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b907b6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/82/6/1695.long O'Brien et al. 1993]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5
*[[Prednisone (Sterapred)]] 30 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''28-day cycles'''

===References===
# O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993 Sep 15;82(6):1695-700. [http://www.bloodjournal.org/content/82/6/1695.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8400226 PubMed]
## '''Update:''' Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15;92(4):1165-71. [http://www.bloodjournal.org/content/92/4/1165.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9694704 PubMed]

==HDMP-R {{#subobject:b15642|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
HDMP-R: '''<u>H</u>'''igh '''<u>D</u>'''ose, '''<u>M</u>'''ethyl'''<u>P</u>'''rednisolone, '''<u>R</u>'''ituximab
===Variant #1, 3 cycles {{#subobject:89350e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289283/ Castro et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Methylprednisolone (Solumedrol)]] 1000 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 to 5
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days 1, 3, 5, 8, 17, 22
**Cycles 2 & 3: 375 mg/m<sup>2</sup> IV once per day on days 1, 7, 14, 21

'''28-day cycle for 3 cycles'''
===Variant #2, 6 cycles {{#subobject:323ca5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.3109/10428194.2011.562572 Pileckyte et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Methylprednisolone (Solumedrol)]] 1000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 50 mg IV once on day 1, then 150 mg IV once on day 2, then remainder of a 375 mg/m<sup>2</sup> dose on day 3, then 500 mg/m<sup>2</sup> IV once on day 5
**Cycles 2 to 6: 500 mg/m<sup>2</sup> IV once per day on days 1 & 5

====Supportive medications====
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/sulfamethoxazole]] "or an equivalent antibiotic throughout the treatment period and up to 6 months after the completion of therapy"

'''21-day cycle for 6 cycles'''

===References===
# Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008 Nov;22(11):2048-53. Epub 2008 Aug 28. [https://www.nature.com/articles/leu2008214 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289283/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18754025 PubMed]
# Pileckyte R, Jurgutis M, Valceckiene V, Stoskus M, Gineikiene E, Sejoniene J, Degulys A, Zvirblis T, Griskevicius L. Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Jun;52(6):1055-65. [https://www.tandfonline.com/doi/full/10.3109/10428194.2011.562572 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21599591 PubMed]

==Ibrutinib & Ofatumumab {{#subobject:2a71b9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1, concurrent ibrutinib and ofatumumab {{#subobject:e85085|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536539/ Jaglowski et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
''This study to patients who had failed two or more prior therapies, or had Richter's transformation.''
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day
*[[Ofatumumab (Arzerra)]] as follows:
**Dose 1: 300 mg IV once on day 1
**Doses 2 to 8: 2000 mg IV once per week on weeks 2 to 8
**Doses 9 to 12: 2000 mg IV once per month on weeks 13, 17, 21, 25

'''One course; ibrutinib given until progression of disease or unacceptable toxicity'''

===Variant #2, ibrutinib lead-in {{#subobject:3ac7f5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536539/ Jaglowski et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
''This study to patients who had failed two or more prior therapies, or had Richter's transformation.''
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day
*[[Ofatumumab (Arzerra)]] as follows:
**Dose 1: 300 mg IV once on week 5
**Doses 2 to 8: 2000 mg IV once per week on weeks 6 to 12
**Doses 9 to 12: 2000 mg IV once per month on weeks 17, 21, 25, 29

'''One course; ibrutinib given until progression of disease or unacceptable toxicity'''

===Variant #3, ofatumumab lead-in {{#subobject:a6c1e7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536539/ Jaglowski et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
''This study to patients who had failed two or more prior therapies, or had Richter's transformation.''
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day, starting on week 9
*[[Ofatumumab (Arzerra)]] as follows:
**Dose 1: 300 mg IV once on day 1
**Doses 2 to 8: 2000 mg IV once per week on weeks 2 to 8
**Doses 9 to 12: 2000 mg IV once per month on weeks 13, 17, 21, 25

'''One course; ibrutinib given until progression of disease or unacceptable toxicity'''

===References===
<!-- Presented in part as a poster presentation at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, May 30 to June 3, 2014, and as an oral presentation at the 2012 ASCO Annual Meeting, Chicago, IL, June 1 to 5, 2012. -->
# Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015 Aug 13;126(7):842-50. Epub 2015 Jun 26. [http://www.bloodjournal.org/content/126/7/842.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536539/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26116658 PubMed]

==Ibrutinib & Rituximab {{#subobject:503e48|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:673f95|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70335-3/fulltext Burger et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
''This study was open to patients with high-risk CLL (del17p or TP53 mutation, PFS less than 36 months from initial therapy, or relapsed CLL with del11q). Only 4 patients in the published study were untreated.''
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week for 4 weeks, then once per month until cycle 6

'''28-day cycles; ibrutinib given until progression of disease or unacceptable toxicity'''

===References===
<!-- # '''Abstract:''' Michael J. Keating, William G. Wierda, Julia Hoellenriegel, Ghayathri Jeyakumar, Alessandra Ferrajoli, Stefan H. Faderl, Marylou Cardenas-Turanzas, Susan Lerner, Gracy Zacharian, Xuelin Huang, Hagop M. Kantarjian, Susan O'Brien. Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients. Blood Nov 2013,122(21)675. [http://www.bloodjournal.org/content/122/21/675 link to original abstract] -->
# Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep;15(10):1090-9. Epub 2014 Aug 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70335-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174348/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25150798 PubMed]
## '''Update:''' Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemia. Clin Cancer Res. 2017 May 1;23(9):2154-2158. Epub 2016 Oct 19. [http://clincancerres.aacrjournals.org/content/23/9/2154 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397369/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27797975 PubMed]

==Idelalisib monotherapy {{#subobject:b872c5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5cabd0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039496/ Gopal et al. 2014 (DELTA)]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123414/ Brown et al. 2014]
|style="background-color:#91cf61"|Phase I, >20 pts
|-
|}
====Chemotherapy====
*[[Idelalisib (Zydelig)]] 150 mg PO twice per day

'''Continued until progression, death, or unacceptable toxicity'''

===References===
# '''DELTA:''' Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008-18. Epub 2014 Jan 22. [https://www.nejm.org/doi/full/10.1056/NEJMoa1314583 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039496/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24450858 PubMed]
## '''Update:''' '''Abstract:''' Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD, PhD, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, PhD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD and Gilles Andre Salles, MD, PhD. Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). ASH Annual Meeting 2014, Abstract 1708 [https://ash.confex.com/ash/2014/webprogram/Paper74940.html link to abstract]
# '''Phase 1:''' Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29;123(22):3390-7. Epub 2014 Mar 10. [http://www.bloodjournal.org/content/123/22/3390 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123414/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24615777 PubMed]

==Lenalidomide monotherapy {{#subobject:a19994|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:5e49d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/34/5343.long Chanan-Khan et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 5 mg PO once per day, escalated by 5 mg every 1 to 2 weeks to a target maximum dose of 25 mg PO once per day on days 1 to 21

====Supportive medications====
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day, starting 2 to 3 days prior to therapy, and continued up to a total of 14 days

'''28-day cycles'''

===Variant #2 {{#subobject:787570|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082321/ Ferrajoli et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day, then increased by 5 mg every 28 days to a target maximum dose of 25 mg PO once per day

'''28-day cycles'''

===Variant #3 {{#subobject:a12f10|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/27/32/5404.full Witzig et al. 2009 (NHL-001)]
|style="background-color:#ffffbe"|Phase II, <20 patients in this subgroup
|-
|}

''Patients studied in this trial and in this subgroup had a diagnosis of SLL.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

'''28-day cycles until disease progression or unacceptable toxicity'''

===References===
<!-- Presented in part at the XI International Workshop on Chronic Lymphocytic Leukemia, September 16–18, 2005, Brooklyn, NY; the 47th Annual Meeting of the American Society of Hematology, December 10–13, 2005, Atlanta, GA; and the 41st Annual Meeting of the American Society of Clinical Oncology, May 13–17, 2005, Orlando, FL. -->
# Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006 Dec 1;24(34):5343-9. Epub 2006 Nov 6. [http://jco.ascopubs.org/content/24/34/5343.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17088571 PubMed]
# Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Jun 1;111(11):5291-7. Epub 2008 Mar 11. [http://www.bloodjournal.org/content/111/11/5291.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082321/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18334676 PubMed]
<!-- Presented in part in poster format at the 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2007, the 49th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 8-11, 2007, and the 13th Annual Meeting of the European Hematology Association, Copenhagen, Denmark, June 12-15, 2008. -->
# Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5404-9. Epub 2009 Oct 5. [http://jco.ascopubs.org/content/27/32/5404.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19805688 PubMed]

==Lenalidomide & Ofatumumab {{#subobject:2f1b19|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:fe2be4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118034/ Vitale et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day, starting on day 9 of cycle 1
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
**Cycles 3 to 6: 1000 mg IV once on day 1
**Cycles 7 to 24: 1000 mg IV once on day 1 ''of every other cycle''

====Supportive medications====
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day on days 1 to 14 of cycle 1
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] use allowed per [http://jop.ascopubs.org/content/2/4/196.full 2006 ASCO guidelines] 
*"No anti-infectious, venous thromboembolism (VTE), or TFR prophylaxis was mandated"

'''28-day cycle for 24 cycles'''

''Patients with a sustained PR or CR were allowed to continue treatment with lenalidomide monotherapy indefinitely.''

===References===
# Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res. 2016 May 15;22(10):2359-67. Epub 2016 Jan 5. [http://clincancerres.aacrjournals.org/content/22/10/2359.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118034/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26733610 PubMed]

==Lenalidomide & Rituximab {{#subobject:e5598d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:cbc465|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/34/5343.long Chanan-Khan et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 5 mg PO once per day, escalated by 5 mg every 1 to 2 weeks to a target maximum dose of 25 mg PO once per day on days 1 to 21
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 
**Subsequent Cycles: 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

====Supportive medications====
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day, starting 2 to 3 days prior to therapy, and continued up to a total of 14 days

'''28-day cycles'''

===Variant #2 {{#subobject:3b76d7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878047/ Badoux et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] as follows:
**Cycle 1: 10 mg PO once per day on days 9 to 28
**Subsequent Cycles: 10 mg PO once per day on days 1 to 28
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 
**Cycle 2: no rituximab given
**Cycles 3 to 12: 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Allopurinol (Zyloprim)]] (dose/schedule not specified) on days 1 to 14 of cycle 1 
*No mandatory antibacterial, antiviral, DVT, or tumor flare prophylaxis
*Growth factor use allowed per [http://jop.ascopubs.org/content/2/4/196.full 2006 ASCO guidelines] 

'''28-day cycle for 12 cycles'''

''Lenalidomide could continue indefinitely in responders.''

===References===
<!-- Presented in part at the XI International Workshop on Chronic Lymphocytic Leukemia, September 16–18, 2005, Brooklyn, NY; the 47th Annual Meeting of the American Society of Hematology, December 10–13, 2005, Atlanta, GA; and the 41st Annual Meeting of the American Society of Clinical Oncology, May 13–17, 2005, Orlando, FL. -->
# Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006 Dec 1;24(34):5343-9. Epub 2006 Nov 6. [http://jco.ascopubs.org/content/24/34/5343.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17088571 PubMed]
<!-- Presented in part at the 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011, and the 52nd Annual Meeting of the American Society of Hematology, Orlando, FL, December 4-7, 2010. -->
# Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2013 Feb 10;31(5):584-91. Epub 2012 Dec 26. [http://jco.ascopubs.org/content/31/5/584.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878047/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23270003 PubMed]

==Obinutuzumab monotherapy {{#subobject:97dd49|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:a20fcb|Variant=1}}=== 
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/119/22/5126.long Salles et al. 2012 (GAUGUIN)]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Note: Dose here is the phase II dose reported in the Cartron et al. 2014 update.''
====Chemotherapy====
*[[Obinutuzumab (Gazyva)]] as follows:
**Cycle 1: 1000 mg IV once per day on days 1, 8, 15 
**Cycle 2 onwards: 1000 mg IV once on day 1

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 650 to 1000 mg PO 30 minutes prior to first infusion, repeat for those at risk of tumor lysis or with history of reaction
*[[:Category:Antihistamines|Antihistamine]] (no drug or dose specified) PO 30 minutes prior to first infusion, repeat for those at risk of tumor lysis or with history of reaction
*[[:Category:Steroids|Corticosteroids]] (no drug/dose/route specified) before first infusion for patients at "high risk" of severe infusion reaction, including those with a history of severe [[Rituximab (Rituxan)]] reactions

'''21-day cycle up to 10 doses (8 cycles)'''

===References===
# '''GAUGUIN:''' Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012 May 31;119(22):5126-32. Epub 2012 Mar 19. [http://www.bloodjournal.org/content/119/22/5126.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22431570 PubMed]
## '''Subgroup analysis:''' Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, Salles GA. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2912-9. Epub 2013 Jul 8. [http://jco.ascopubs.org/content/31/23/2912.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835718 PubMed]
## '''Subgroup analysis:''' Salles GA, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, Cartron G. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2920-6. Epub 2013 Jul 8. [http://jco.ascopubs.org/content/31/23/2920.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835715 PubMed]
## '''Subgroup analysis:''' Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G, Wenger M, Wassner-Fritsch E, Hallek M. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014 Oct 2;124(14):2196-202. Epub 2014 Aug 20. [http://www.bloodjournal.org/content/124/14/2196 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25143487 PubMed]

==OFAR {{#subobject:6c2942|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
OFAR: '''<u>O</u>'''xaliplatin, '''<u>F</u>'''ludarabine, '''<u>A</u>'''ra-C (Cytarabine), '''<u>R</u>'''ituximab

===Regimen {{#subobject:776e7d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/26/2/196.full Tsimberidou et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Oxaliplatin (Eloxatin)]] 25 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 4
*[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV once per day on days 2 & 3, '''administered within 30 minutes of completion of oxaliplatin'''
*[[Cytarabine (Cytosar)]] 1000 mg/m<sup>2</sup> IV over 2 hours once per day on days 2 & 3, '''4 hours after fludarabine started'''
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV over 4 to 6 hours once on day 3
**Cycles 2 to 6: 375 mg/m<sup>2</sup> IV over 4 to 6 hours once on day 1

====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 6
*Herpes zoster and PCP (Pneumocystis jiroveci pneumonia) prophylaxis used

'''28-day cycle for up to 6 cycles'''

===References===
<!-- Presented in part at the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL, and at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA. -->
# Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10;26(2):196-203. [http://jco.ascopubs.org/content/26/2/196.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18182662 PubMed]

==PCR {{#subobject:d3f558|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PCR: '''<u>P</u>'''entostatin, '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''ituximab

===Regimen {{#subobject:ebf988|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/10/1575.long Lamanna et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pentostatin (Nipent)]] 4 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: no dose
**Cycles 2 to 6: 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*''Note: paper says they were "administered prophylactically," without additional details.''
*[[Filgrastim (Neupogen)]]
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 
*[[Acyclovir (Zovirax)]]

'''21-day cycle for 6 cycles'''

===References===
# Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006 Apr 1;24(10):1575-81. Epub 2006 Mar 6. [http://jco.ascopubs.org/content/24/10/1575.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16520464 PubMed]

==R-BAC {{#subobject:f44525|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-BAC: '''<u>R</u>'''ituximab, '''<u>B</u>'''endamustine, '''<u>A</u>'''ra-'''<u>C</u>''' (Cytarabine)

===Regimen {{#subobject:c74f36|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/ajh.23391/full Visco et al. 2013]
|style="background-color:#ffffbe"|Pilot, <20 patients reported
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1
**Subsequent cycles: 500 mg/m<sup>2</sup> IV once on day 1
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Cytarabine (Cytosar)]] 800 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 3, '''beginning 2 hours after bendamustine'''

====Supportive medications==== 
*Primary prophylaxis with [[:Category:Granulocyte_colony-stimulating_factors|granulocyte colony-stimulating factor]] was routinely used starting from Day 5 after chemotherapy completion, and lasting for 3 to 6 days or until neutrophil count recovery.

'''28-day cycle for up to 4 cycles with dose delay and modification based on response and toxicity'''

===References===
# Visco C, Finotto S, Pomponi F, Sartori R, Laveder F, Trentin L, Paolini R, Di Bona E, Ruggeri M, Rodeghiero F. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. Am J Hematol. 2013 Apr;88(4):289-93. Epub 2013 Feb 28. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23391/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23450436 PubMed]

==Ruxolitinib monotherapy {{#subobject:ccaffa |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:cbe4fe |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30194-6/fulltext Jain et al. 2017]
|style="background-color:#ffffbe"|Phase II, <20 pts in this subgroup
|-
|}
''Note: this was a trial focused on symptom control, not efficacy.''
====Chemotherapy====
*[[Ruxolitinib (Jakafi)]] 10 mg PO twice per day

===References===
# Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb;4(2):e67-e74. Epub 2017 Jan 11. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30194-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356368/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28089238 PubMed]

==Venetoclax monotherapy {{#subobject:b479ff|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, standard lead-in {{#subobject:1aa538|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1513257 Roberts et al. 2015 (M12-175)]
|style="background-color:#91cf61"|Phase I/II
| style="background-color:#e0ecf4" |ORR: 79%
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30019-5/fulltext Stilgenbauer et al. 2016 (M13-982)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#e0ecf4" |ORR: 79% (95% CI, 70.5-87)
|-
|[http://www.bloodjournal.org/content/131/15/1704.long Coutre et al. 2018 (M14-032)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#bfd3e6" |ORR: 67%
|-
|}
''This is the dosing schedule used in the phase II expansion cohort of '''Roberts et al. 2015'''. See paper for supportive care details during initial dosing.''
====Chemotherapy====
*[[Venetoclax (Venclexta)]] as follows:
**Week 1: 20 mg PO once per day
**Week 2: 50 mg PO once per day
**Week 3: 100 mg PO once per day
**Week 4: 200 mg PO once per day
**Week 5 onwards: 400 mg PO once per day

'''Continued until disease progression or unacceptable toxicity'''

===Variant #2, modified lead-in {{#subobject:65ad03|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/131/15/1704.long Coutre et al. 2018 (M14-032)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#bfd3e6" |ORR: 67%
|-
|}
''This dosing schedule was intended for high-risk patients with "clinical signs of progression during screening." See paper for supportive care details during initial dosing.''
====Chemotherapy====
*[[Venetoclax (Venclexta)]] as follows:
**Day 1: 20 mg PO once per day
**Days 2 & 3: 50 mg PO once per day
**Days 4 to 7: 100 mg PO once per day
**Week 2: 200 mg PO once per day
**Week 3 onwards: 400 mg PO once per day

'''Continued until disease progression or unacceptable toxicity'''

===References===
<!-- # '''Abstract:''' Shuo Ma, John Francis Seymour, Mark C. Lanasa, Thomas J. Kipps, Jacqueline Claudia Barrientos, Matthew Steven Davids, Tanita Mason-Bright, Nikita Rudersdorf, Jianning Yang, Wijith Munasinghe, Ming Zhu, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, Andrew Warwick Roberts. ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. J Clin Oncol 32:5s, 2014 (suppl; abstr 7013) [http://meetinglibrary.asco.org/content/132375-144 link to abstract] -->
# '''M12-175:''' Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):311-22. Epub 2015 Dec 6. [https://www.nejm.org/doi/full/10.1056/NEJMoa1513257 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26639348 PubMed]
<!-- Stilgenbauer S, Eichhorst, B.F., Schetelig, J., Coutre, S., Seymour, J.F., Munir, T., Puvvada, S.D., Wendtner, C.M., Roberts, A.W., Jurczak, W., Mulligan, S. and Boettcher, S., 2015. Venetoclax (ABT-199/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion: results of the pivotal international phase 2 study. Blood 2015;126:Abstract LBA-6 -->
# '''M13-982:''' Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Heitner Enschede S, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768-78. Epub 2016 May 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30019-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27178240 PubMed]
## '''Update:''' Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018 Jul 1;36(19):1973-1980. Epub 2018 May 1. [https://www.ncbi.nlm.nih.gov/pubmed/29715056 PubMed]
# '''M14-032:''' Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 Apr 12;131(15):1704-1711. Epub 2018 Jan 5. [http://www.bloodjournal.org/content/131/15/1704.long link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/29305552 PubMed]

=Consolidation and/or maintenance after subsequent lines of therapy=

==FC, then allo HSCT {{#subobject:1a1ed9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FC: '''<u>F</u>'''ludarabine & '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:886e40|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/116/14/2438 Dreger et al. 2010 (GCLLSG CLL3X)]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Allogeneic HSCT|886e40}}
===References===
<!-- Presented in part in abstract form at the 50th annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2008. -->
# '''GCLLSG CLL3X:''' Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010 Oct 7;116(14):2438-47. Epub 2010 Jul 1. [http://www.bloodjournal.org/content/116/14/2438 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20595516 PubMed]
## '''Update:''' Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013 Apr 18;121(16):3284-8. Epub 2013 Feb 22. [http://www.bloodjournal.org/content/121/16/3284.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23435461 PubMed]
## '''Update:''' Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 Sep 21;130(12):1477-1480. Epub 2017 Jul 17. [http://www.bloodjournal.org/content/130/12/1477.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28716861 PubMed]

==Fludarabine & TBI, then allo HSCT {{#subobject:53c6af|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7fa6ce|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/16/3819.long Sorror et al. 2005]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Allogeneic HSCT|7fa6ce}}
===References===
<!-- Presented in part at the Tandem Bone Marrow Transplantation meeting, February 13-17, 2004, Orlando, FL (for part of the patient population). -->
# Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 1;23(16):3819-29. Epub 2005 Apr 4. [http://jco.ascopubs.org/content/23/16/3819.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15809448 PubMed]
## '''Update:''' Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, Agura E, Chauncey TR, Pulsipher MA, McSweeney PA, Wade JC, Bruno B, Langston A, Radich J, Niederwieser D, Blume KG, Storb R, Maloney DG. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008 Oct 20;26(30):4912-20. Epub 2008 Sep 15. [http://jco.ascopubs.org/content/26/30/4912.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652085/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18794548 PubMed]

==Fludarabine, Busulfan, ATG, then allo HSCT {{#subobject:ed545b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e2c4bf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/91/3/756.full Slavin et al. 1998]
| style="background-color:#91cf61" |Phase II
|-
|[http://jco.ascopubs.org/content/21/14/2747.long Schetelig et al. 2003]
|style="background-color:#91cf61"|Phase II
|-
|}
{{#lst:Allogeneic HSCT|e2c4bf}}
===References===
# Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756-63. [http://www.bloodjournal.org/content/91/3/756.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9446633 PubMed]
# Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003 Jul 15;21(14):2747-53. [http://jco.ascopubs.org/content/21/14/2747.long link to original article] '''contains reference to protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12860954 PubMed]
==Fludarabine, Cyclophosphamide, ATG, then allo HSCT {{#subobject:f2ce14|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:3e71d0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/116/14/2438 Dreger et al. 2010 (GCLLSG CLL3X)]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Allogeneic HSCT|3e71d0}}
===References===
<!-- Presented in part in abstract form at the 50th annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2008. -->
# '''GCLLSG CLL3X:''' Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010 Oct 7;116(14):2438-47. Epub 2010 Jul 1. [http://www.bloodjournal.org/content/116/14/2438 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20595516 PubMed]
## '''Update:''' Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013 Apr 18;121(16):3284-8. Epub 2013 Feb 22. [http://www.bloodjournal.org/content/121/16/3284.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23435461 PubMed]
## '''Update:''' Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 Sep 21;130(12):1477-1480. Epub 2017 Jul 17. [http://www.bloodjournal.org/content/130/12/1477.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28716861 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00143-6/fulltext van Oers et al. 2015 (PROLONG)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Ofatumumab_monotherapy_3|Ofatumumab]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30045-X/fulltext Greil et al. 2016 (AGMT CLL-8a)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy_4|Rituximab]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''No further treatment offered to patients in their second or third CR or PR; prior treatment was not specified in '''PROLONG'''. 
====Preceding treatment====
*AGMT CLL-8a: "Rituximab-containing chemoimmunotherapy"

===References===
# '''PROLONG:''' van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD, Gupta I, Phillips J, Williams V, Manson S, Lisby S, Geisler C; PROLONG study investigators. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015 Oct;16(13):1370-9. Epub 2015 Sep 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00143-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26377300 PubMed]
# '''AGMT CLL-8a:''' Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016 Jul;3(7):e317-29. Epub 2016 Jun 16. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30045-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27374465 PubMed]

==Ofatumumab monotherapy {{#subobject:9a07b6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:134c67|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00143-6/abstract van Oers et al. 2015 (PROLONG)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_3|Observation]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Treatment offered to patients in their second or third CR or PR; prior treatment was not specified.''
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] 300 mg IV once, then 1000 mg IV one week later and every 8 weeks

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg PO 30 to 120 minutes prior to each infusion
*[[Diphenhydramine (Benadryl)]] 50 mg IV or PO 30 to 120 minutes prior to each infusion, or equivalent [[:Category:Antihistamines|antihistamine]]
*[[Prednisolone (Millipred)]] 50 mg IV 30 to 120 minutes prior to each infusion, or equivalent [[:Category:Steroids|glucocorticoid]]

'''Up to 2-year course'''

===Variant #2 {{#subobject:e5c8d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13380/full Österborg et al. 2015 (GEN416)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Ofatumumab_monotherapy_3|Ofatumumab]] x 8
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] 2000 mg IV once per month

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg PO once prior to each infusion
*[[Cetirizine (Zyrtec)]] (or equivalent [[:Category:Antihistamines|antihistamine]]) 10 mg PO once prior to each infusion

'''Up to 2 years (24 doses)'''

===References===
# '''GEN416:''' Österborg A, Wierda WG, Mayer J, Hess G, Hillmen P, Schetelig J, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Kozlowski P, Pfreundschuh M, Rizzi R, Spacek M, Phillips JL, Gupta IV, Williams V, Jewell RC, Nebot N, Lisby S, Dyer MJ. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2015 Jul;170(1):40-9. Epub 2015 Mar 30. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13380/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25825041 PubMed]
# '''PROLONG:''' van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD, Gupta I, Phillips J, Williams V, Manson S, Lisby S, Geisler C; PROLONG study investigators. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015 Oct;16(13):1370-9. Epub 2015 Sep 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00143-6/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26377300 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30168-0/fulltext Chanan-Khan et al. 2017 (CONTINUUM)]
|style="background-color:#1a9851"|Phase III (C)
|Lenalidomide
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''No active antineoplastic treatment offered to patients with at least partial response to second-line therapy.'' 

===References===
# '''CONTINUUM:''' Chanan-Khan AA, Zaritskey A, Egyed M, Vokurka S, Semochkin S, Schuh A, Kassis J, Simpson D, Zhang J, Purse B, Foà R. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2017 Nov;4(11):e534-e543. Epub 2017 Sep 25. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30168-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28958469 PubMed]

==Rituximab monotherapy {{#subobject:a88421|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d67fca|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30045-X/fulltext Greil et al. 2016 (AGMT CLL-8a)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_3|Observation]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Preceding treatment====
*"Rituximab-containing chemoimmunotherapy"
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 3 months

'''2 years total (8 doses)'''

===References===
# '''AGMT CLL-8a:''' Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016 Jul;3(7):e317-29. Epub 2016 Jun 16. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30045-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27374465 PubMed]

=Prognosis=
These are various staging and risk prediction systems that are in approximate chronological order.
==Original Rai staging (1975)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*'''Stage 0:''' bone marrow and blood lymphocytosis only
*'''Stage I:''' lymphocytosis with enlarged nodes
*'''Stage II:''' lymphocytosis with enlarged spleen or liver or both
*'''Stage III:''' lymphocytosis with anemia
*'''Stage IV:''' lymphocytosis with thrombocytopenia
# Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34. [http://www.bloodjournal.org/content/46/2/219.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8652811 PubMed]

==Binet staging (1981)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*'''Group A:''' no anemia, no thrombocytopenia, less than three involved areas
*'''Group B:''' no anemia, no thrombocytopenia, three or more involved areas (counting as one each of the following: axillary, cervical, inguinal, lymph nodes, whether unilateral or bilateral, spleen and liver)
*'''Group C:''' anemia (hemoglobin less than 10 g/dL) and/or thrombocytopenia (platelets less than 100 x 10<sup>9</sup>/L)
# Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1;48(1):198-206. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19810701)48:1%3C198::AID-CNCR2820480131%3E3.0.CO;2-V/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7237385 PubMed]

==Risk by karyotype (1984)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
''Classic NEJM paper establishing abnormal karyotype as an adverse prognostic marker''
# Han T, Ozer H, Sadamori N, Emrich L, Gomez GA, Henderson ES, Bloom ML, Sandberg AA. Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia. N Engl J Med. 1984 Feb 2;310(5):288-92. [https://www.nejm.org/doi/full/10.1056/NEJM198402023100504link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6690952 PubMed]

==Risk by lymphocyte doubling time==
# Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986 Mar;62(3):567-75. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.1986.tb02969.x/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3954968 PubMed]
# Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer. 1987 Dec 1;60(11):2712-6. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19871201)60:11%3C2712::AID-CNCR2820601122%3E3.0.CO;2-1/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3677006 PubMed]

==Risk by FISH==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*''Classic 2000 NEJM paper establishing that 17p deletion has the worst prognosis:''
# Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 28;343(26):1910-6. [https://www.nejm.org/doi/full/10.1056/NEJM200012283432602 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11136261 PubMed]
*''This article and abstract explore the significance of 13q deletions in more detail:''
# Van Dyke DL, Shanafelt TD, Call TG, Zent CS, Smoley SA, Rabe KG, Schwager SM, Sonbert JC, Slager SL, Kay NE. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol. 2010 Feb;148(4):544-50. Epub 2009 Nov 6. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.07982.x/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2866061/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19895615 PubMed] 
# '''Abstract:''' Claudia Haferlach, Melanie Zenger, Vera Grossmann, Frank Dicker, Sabine Jeromin, Alexander Kohlmann, Susanne Schnittger, Wolfgang Kern, Torsten Haferlach. The Impact of Homozygosity and Size of the 13q Deletion in Patients with CLL. Blood 2012 120:3892 abstract 3892 [http://www.bloodjournal.org/content/120/21/3892 link to abstract]

==Risk by TP53 mutation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
# Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010 Oct 10;28(29):4473-9. Epub 2010 Aug 9. [http://ascopubs.org/doi/full/10.1200/JCO.2009.27.8762 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20697090 PubMed]

==Risk by CD38 expression==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
# Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1840-7. [http://www.bloodjournal.org/content/94/6/1840 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10477712 PubMed]
# '''Review:''' Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011 Sep 29;118(13):3470-8. [http://www.bloodjournal.org/content/118/13/3470 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574275/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21765022 PubMed]

==Risk by ZAP-70 expression (2003)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
# Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003 May 1;348(18):1764-75. [https://www.nejm.org/doi/full/10.1056/NEJMoa023143 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12724482 PubMed]

==Prognostic scoring system using molecular and cytogenetic features (2012)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
# Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, Deambrogi C, Khiabanian H, Serra R, Bertoni F, Forconi F, Laurenti L, Marasca R, Dal-Bo M, Rossi FM, Bulian P, Nomdedeu J, Del Poeta G, Gattei V, Pasqualucci L, Rabadan R, Foà R, Dalla-Favera R, Gaidano G. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013 Feb 21;121(8):1403-12. Epub 2012 Dec 13. [http://www.bloodjournal.org/content/121/8/1403.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578955/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23243274 PubMed]

==CLL-IPI (2016)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*[https://www.qxmd.com/calculate/calculator_375/cll-ipi QxMD calculator]
# International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016 Jun;17(6):779-90. Epub 2016 May 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30029-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27185642 PubMed]

[[Category:Chronic lymphocytic leukemia (CLL/SLL) regimens]]
[[Category:Disease-specific pages]]
[[Category:Indolent lymphomas]]
